[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 471
1. Goto H, Ikenaga M, Yasui M, Miyazaki M, Mishima H, Tsujie M, Miyamoto A, Hirao M, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2659-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation].
  • A 76-year-old woman consulted her local physician because she experienced anal pain during defecation.
  • She was diagnosed with squamous cell anal carcinoma and underwent chemoradiation (59.4 Gy + UFT 500 mg/5 days/week).
  • She was followed up and 8 months later, she experienced anal erosion and pain.
  • Functional preservation employing concomitant chemoradiation has become the standard treatment for most case of squamous cell anal carcinoma, with APR backup being a salvage procedure.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224671.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


2. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT: Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal; 2007;21(3):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both of these benign tumors are known to be at risk of developing into cancer.
  • During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.
  • It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.


3. Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, Bouvet E, Soulé JC, Leport C, Duval X: Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS; 2007 Jul 11;21(11):1457-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors.
  • OBJECTIVE: To assess the prevalence of and factors associated with squamous intraepithelial lesions and condyloma [human papillomavirus (HPV)-related lesions) in HIV-infected patients.
  • RESULTS: Of 473 patients examined, (200 homosexual men, 123 heterosexual men, 150 women), 108 (23%) had histologically confirmed anal HPV-related lesions (36, 15 and 11% of the respective populations), including 51 (47%) with only endoanal localization.
  • Among these 108 patients, histological dysplasia of grades I or II and grade III were noted in 59 and two patients, respectively, invasive endoanal cancer in one; three patients also had high-risk oncogenicity HPV without dysplasia.
  • Independent identified associated factors of HPV-related condyloma were the number of incidents of sexual intercourse per month [odds ratio (OR) 1.04; 95% confidence interval (CI) 1.01-1.06], CD4 cell count below 200 x 10 cells/l (OR 3.22; 95% CI 1.37-7.60), history of anal HPV lesion (OR 4.57; 95% CI 2.13-9.81), and receptive anal intercourse (OR 2.30; 95% CI 1.11-4.77).
  • The two latter factors remained associated with histological dysplasia (OR 2.82; 95% CI 1.38-5.76 for history of anal condyloma, and OR 4.29; 95% CI 2.18-8.44 for receptive anal intercourse).
  • [MeSH-minor] Adult. Anal Canal / pathology. Anal Canal / virology. Cross-Sectional Studies. Female. Heterosexuality. Homosexuality. Humans. In Situ Hybridization. Male. Middle Aged. Odds Ratio. Papilloma / diagnosis. Papilloma / pathology. Papilloma / virology. Prevalence. Risk


Advertisement
4. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK, Infectious Disease Clinical Research Program HIV Working Group: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS; 2010 Feb 20;24(4):535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.
  • OBJECTIVE: To evaluate the incidence rates of anal cancer over the HIV epidemic and assess the impact of HAART use on anal cancer events.
  • METHODS: We evaluated the incidence of and factors associated with anal cancer using longitudinal data from the prospective U.S.
  • RESULTS: Among 4506 HIV-infected men with 37 806 person-years of follow-up, anal cancer rates (per 100 000 person-years) increased five-fold, from 11 in the pre-HAART to 55 in the HAART era (P = 0.02).
  • At cancer diagnosis (n = 19), median age was 42 years, median CD4 cell count was 432 cells/microl, 74% had a CD4 nadir cell count less than 200 cells/microl, 42% had a prior AIDS event, and 74% had received HAART.
  • From separate models, prior AIDS event (hazard ratio 3.88, P = 0.01) and lower CD4 nadir (hazard ratio 0.85 per 50 cell, P = 0.03) were associated with anal cancer, with a trend for a history of gonorrhea (hazard ratio 2.43, P = 0.07).
  • Duration of HAART use was not associated with a reduced risk of anal cancer (hazard ratio 0.94, P = 0.42).
  • CONCLUSION: Incidence rates of anal cancer have progressively increased during the HIV epidemic.
  • Persons with a longer duration of HIV infection have a substantially higher rate of anal cancer.
  • As HIV-infected persons are experiencing longer life expectancies and HAART does not appear protective of anal cancer, studies on preventive strategies are needed.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):256-62 [11242198.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):524-30 [19127538.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Ann Intern Med. 1999 Oct 5;131(7):502-6 [10507958.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Am J Surg. 2005 Nov;190(5):732-5 [16226949.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2892-900 [18980293.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • (PMID = 19926961.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / NIAID NIH HHS / AI / Y01 AI005072; United States / PHS HHS / / HU0001-05-2-0011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS203436; NLM/ PMC3132114
  • [Investigator] Banks S; Bavaro M; Chun H; Decker C; Eberly L; Eggleston C; Hairston H; Hawkes C; Johnson A; Landrum M; Lifson A; Merritt S; O'Connell R; Okulicz J; Peel S; Polis M; Powers J; Tramont E; Whitman T; Wortmann G; Zapor M
  •  go-up   go-down


5. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Franceschi S, De Vuyst H: Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS; 2009 Jan;4(1):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus vaccines and anal carcinoma.
  • PURPOSE OF REVIEW: To explore the possible role of current prophylactic vaccines against human papillomavirus (HPV) in the prevention of anal intraepithelial neoplasia and squamous cell carcinoma of the anus (SCCA).
  • In addition, more than 90% prevalence of HPV was found in anal intraepithelial neoplasia.
  • Answers to some still open questions, notably vaccine efficacy in men and HIV-infected individuals and willingness to expand vaccination programmes to both sexes, are essential to predict the ultimate impact of HPV vaccines on the prevention of cancerous and precancerous anal lesions.
  • [MeSH-major] Anus Neoplasms / prevention & control. Carcinoma in Situ / prevention & control. Carcinoma, Squamous Cell / prevention & control. HIV Infections / complications. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19339940.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Papillomavirus Vaccines
  • [Number-of-references] 56
  •  go-up   go-down


7. Kleiner-Hancock HE, Shi R, Remeika A, Robbins D, Prince M, Gill JN, Syed Z, Adegboyega P, Mathis JM, Clifford JL: Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts. BMC Cancer; 2010 Jul 26;10:394
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: NF-kappaB is a survival signaling transcription factor complex involved in the malignant phenotype of many cancers, including squamous cell carcinomas (SCC).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):148-55 [10761701.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1441-6 [11801687.001]
  • [Cites] Carcinogenesis. 2001 Jan;22(1):73-82 [11159744.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Nucl Med Biol. 2002 Feb;29(2):263-73 [11823132.001]
  • [Cites] J Agric Food Chem. 2002 May 22;50(11):3193-6 [12009985.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Dev Dyn. 2003 Feb;226(2):237-44 [12557202.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):768-80 [14570043.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Methods Enzymol. 1981;77:398-405 [7329316.001]
  • [Cites] J Biol Chem. 1986 Jan 25;261(3):1372-8 [2418014.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5097-101 [3621194.001]
  • [Cites] Curr Opin Cell Biol. 1994 Dec;6(6):825-31 [7880529.001]
  • [Cites] Jpn J Cancer Res. 1996 Apr;87(4):349-56 [8641965.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):386-91 [8784473.001]
  • [Cites] Jpn J Cancer Res. 1997 May;88(5):443-52 [9247600.001]
  • [Cites] Jpn J Cancer Res. 1997 Sep;88(9):821-30 [9369929.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4832-9 [9809987.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7383-92 [15905586.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2936-42 [16395701.001]
  • [Cites] Biol Chem. 2006 Apr;387(4):387-92 [16606336.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Biosci Biotechnol Biochem. 2006 Dec;70(12):3062-5 [17151446.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2006 Dec;31(24):2049-52 [17357553.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1303-13 [17301064.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1396-408 [17510282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19589-94 [18048326.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 1;366(1):219-25 [18060855.001]
  • [Cites] Free Radic Biol Med. 2008 Dec 15;45(12):1663-73 [18845239.001]
  • [Cites] Cancer Cell. 2009 Apr 7;15(4):283-93 [19345327.001]
  • [Cites] Toxicol Lett. 2009 Mar 28;185(3):180-6 [19150646.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3423-32 [19417020.001]
  • [Cites] Mol Cancer. 2009;8:27 [19432991.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Oct;2(10):903-11 [19789299.001]
  • [Cites] Nucl Med Commun. 2009 Dec;30(12):908-17 [19794320.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Aug;66(3):467-74 [19940992.001]
  • [Cites] Nutr Cancer. 2000;36(2):191-9 [10890030.001]
  • (PMID = 20659317.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1K22CA102005-01A2; United States / NCI NIH HHS / CA / 1R21CA116324
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzyl Alcohols; 0 / Coumarins; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Plant Extracts; 495-02-3 / aurapten; 52946-22-2 / 1'-acetoxychavicol acetate; 5688UTC01R / Tretinoin; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2916922
  •  go-up   go-down


8. Gretschel S, Warnick P, Bembenek A, Dresel S, Koswig S, String A, Hünerbein M, Schlag PM: Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol; 2008 Aug;34(8):890-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal.
  • AIM: Although 15-25% of patients with anal cancer present with superficial inguinal lymph node metastases but the routine application of groin irradiation is controversial because of serious side effects.
  • METHODS: Forty patients with anal cancer underwent 1 ml Tc(99m)-Nanocolloid injection in four sites around the tumour.
  • CONCLUSIONS: Inguinal sentinel node biopsy in anal cancer is efficient and could assist in the decision for inguinal radiation.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178364.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin
  •  go-up   go-down


9. Pereira AC, Lacerda HR, Barros RC: Diagnostic methods for prevention of anal cancer and characteristics of anal lesions caused by HPV in men with HIV/AIDS. Braz J Infect Dis; 2008 Aug;12(4):293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic methods for prevention of anal cancer and characteristics of anal lesions caused by HPV in men with HIV/AIDS.
  • Abnormalities found with anuscopy under colposcopic vision, anal cytology and anal biopsy were evaluated in 21 men with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) at the Federal University of Pernambuco Hospital in Brazil.
  • Mean CD4+ cell count was 482.2 +/- 173.75 cells/mm(3), and 80.9% presented a HIV viral load of < 5,000 copies/mL.
  • Reported sexual preference was 52.4% homosexuals, 28.6% bisexuals, and 19.0%heterosexuals; 81% reported having had receptive anal intercourse and 61.9% reported more than 10 sexual partners of the same sex.
  • Among the 21 anal cytology examinations, seven (33.3%) revealed low-grade squamous intraepithelial lesions (LSIL); three (14.3%) presented atypical squamous cells of undetermined significance (ASCUS) and 11 (52.4%) were normal.
  • Seventeen patients were submitted to anal biopsy with the following findings: three patients (17.6%) with normal epithelium, one (5.9%) with infection by HPV, three (17.6%) with condylomatas, two (11.8%) with AIN 1, four (23.6%) with AIN 2, three (17.6%) with AIN 3, and one (5.9%) with PAIN 2.
  • Anuscopy under colposcopic vision was found to be useful for detecting anal lesions and for guiding anal biopsies.
  • Anal cytology was less useful, as it underestimated the frequency of lesions.


10. Nigriny JF, Wu P, Butler CE: Perineal reconstruction with an extrapelvic vertical rectus abdominis myocutaneous flap. Int J Gynecol Cancer; 2010 Dec;20(9):1609-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 54-year-old woman with a prior history of anal squamous cell carcinoma underwent neoadjuvant chemoradiotherapy followed by abdominoperineal resection, total abdominal hysterectomy, and bilateral salpingo-oophorectomy.
  • Three years later, she developed vulvar squamous cell carcinoma with vascular and lymphatic invasion and underwent radical vulvectomy and distal urethrectomy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Pelvis / surgery. Perineum / surgery. Reconstructive Surgical Procedures / methods. Rectus Abdominis / surgery. Surgical Flaps. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119371.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Small tumors of the anal margin were not included since they were treated by surgical excision only.
  • T categories (International Union against Cancer) were T1 (15), T2 (36), T3 (34), and T4 (16).
  • RESULTS: Overall survival and colostomy-free survival rates for patients with anal canal cancer were 75 percent and 87 percent at five years, respectively.
  • Patients with anal margin cancer had a less favorable outcome with five-year-overall and colostomy-free survival rates of 54 percent and 69 percent, respectively.
  • After correction for imbalance between anal canal and anal margin tumors, i.e., exclusion of T1 tumors of the anal canal, difference in overall survival remained significant (73 percent vs. 54 percent, P = 0.01).
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Tsui IF, Garnis C, Poh CF: A dynamic oral cancer field: unraveling the underlying biology and its clinical implication. Am J Surg Pathol; 2009 Nov;33(11):1732-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dynamic oral cancer field: unraveling the underlying biology and its clinical implication.
  • Oral cancer is a complex disease that is characterized by histologic and genetic heterogeneity.
  • Therefore, some cancer forerunners may remain undetected clinically or histologically.
  • In this report, we used a newly developed optical technique, direct fluorescence visualization, to define a contiguous field that extended beyond the margins of a clinically visible oral squamous cell carcinoma.
  • Genome alterations detected for each specimen were compared to define whether each lesion arose independently or as a consequence of a shared progenitor cell.
  • Our results indicate that the field effect of oral cancer is extremely dynamic, with different genetic alterations present in different biopsies within a field.
  • This case study also demonstrated that 2 genetically unrelated squamous cell carcinoma could be developed within 10 mm at the right lateral tongue of this patient.

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 1999 Jul;35(4):354-9 [10645398.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):396-8 [8746271.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1860-6 [11448897.001]
  • [Cites] Anal Cell Pathol. 2002;24(1):25-39 [12122281.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6447-50 [12438233.001]
  • [Cites] Head Neck. 2003 Jan;25(1):67-73 [12478546.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3607-13 [15173066.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3614-20 [15173067.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):563-8 [6537892.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):943-7 [8074821.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):323-7 [9250145.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2003-6 [9581845.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3636-7 [15201182.001]
  • [Cites] Semin Cancer Biol. 2005 Apr;15(2):113-20 [15652456.001]
  • [Cites] Oncologist. 2005 Aug;10(7):493-500 [16079316.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7561-7 [16140918.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8017-21 [16140975.001]
  • [Cites] Oral Oncol. 2005 Oct;41(9):916-26 [16043381.001]
  • [Cites] BMC Bioinformatics. 2005;6:274 [16297240.001]
  • [Cites] J Biomed Opt. 2006 Mar-Apr;11(2):024006 [16674196.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6716-22 [17121891.001]
  • [Cites] Head Neck. 2007 Jan;29(1):71-6 [16983693.001]
  • [Cites] Ann N Y Acad Sci. 2007 Mar;1098:167-83 [17332080.001]
  • [Cites] Genomics. 2007 May;89(5):647-53 [17276656.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3766-73 [17704426.001]
  • [Cites] BMC Bioinformatics. 2008;9:243 [18492270.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):424-9 [19138989.001]
  • [Cites] J Thorac Oncol. 2009 Feb;4(2):227-39 [19179901.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Apr;266(4):547-51 [18688630.001]
  • [Cites] Cancer Prev Res (Phila). 2009 May;2(5):423-31 [19401530.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):357-62 [10690511.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):429-35 [7619114.001]
  • [Cites] Hum Pathol. 1995 Mar;26(3):251-61 [7890274.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Mar;79(3):321-9 [7621010.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 17;88(8):519-29 [8606380.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2484-7 [8653681.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2488-92 [8653682.001]
  • [Cites] J Oral Pathol Med. 1996 Feb;25(2):49-54 [8667255.001]
  • [Cites] Cancer Prev Res (Phila). 2009 May;2(5):401-4 [19401533.001]
  • (PMID = 19858864.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE17013; United States / NIDCR NIH HHS / DE / DE017013-05; Canada / Canadian Institutes of Health Research / / MOP-77663; United States / NIDCR NIH HHS / DE / R01 DE017013-05; United States / NIDCR NIH HHS / DE / R01 DE017013
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS133695; NLM/ PMC2885153
  •  go-up   go-down


13. Cheng CM, Tsuneyama K, Matsui K, Takahashi H, Ishizawa S, Takano Y: Cytoplasmic expression of c-erbB2 in non-small cell lung cancers. Virchows Arch; 2005 Jun;446(6):596-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic expression of c-erbB2 in non-small cell lung cancers.
  • The aim of this study was to investigate the expression of c-erbB2 in non-small cell lung cancers (NSCLCs) with attention both to membranous and cytoplasmic reaction, and to try to elucidate the meaning of cytoplasmic expression of c-erbB2 in NSCLCs.
  • Immunohistochemical c-erbB2 expression and related clinico-pathological features were examined in 312 surgically resected patient tissues of NSCLCs, including 175 cases of adenocarcinoma and 137 cases of squamous cell carcinoma.
  • Immunostaining of inner- and ecto-domain of c-erbB2, mRNA expression and the quantitation of soluble c-erbB2 in cultured media were performed in five NSCLC cell lines.
  • Cytoplasmic expression of c-erbB2 was observed more frequently than membranous, both in patient tissues and cell lines.
  • Membranous c-erbB2 was expressed by both inner and ecto-domain, while cytoplasmic c-erbB2 was expressed by either or both inner and ecto-domain. c-erbB2 mRNA was produced in most cell lines; however, the soluble form was only detectable in a cell line that only presented a membranous c-erbB2.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Cell Membrane / metabolism. Cytoplasm / metabolism. Lung Neoplasms / metabolism. Receptor, ErbB-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3384-8 [10910043.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Clin Chim Acta. 2002 Aug;322(1-2):11-9 [12104076.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1449-56 [11986780.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):987-93 [8687165.001]
  • [Cites] Int J Biochem Cell Biol. 2003 May;35(5):572-8 [12672450.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 4):51-8 [11894014.001]
  • [Cites] J Clin Lab Anal. 1995;9(3):151-65 [7541455.001]
  • [Cites] Oral Oncol. 1999 May;35(3):302-13 [10621852.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):1983-7 [10561248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2384-8 [6326124.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):734-44 [11895903.001]
  • [Cites] J Leukoc Biol. 2002 May;71(5):753-63 [11994499.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35532-9 [10940298.001]
  • [Cites] Pathol Int. 2001 Jan;51(1):33-6 [11148461.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3819-25 [9042264.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):959-65 [12966408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12847-52 [12239347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(19):6497-501 [2995967.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1089-95 [11378338.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13829-37 [12574167.001]
  • (PMID = 15902485.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


14. Moon KY: The chemopreventive effect of retinoids on cellular NF-kappaB activity induced by NMU and NEU in human malignant keratinocytes. Cancer Res Treat; 2007 Jun;39(2):82-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine the implications of NF-kappaB activation on the chemopreventive role of retinoids and their effect on cellular NF-kappaB activity that's induced by known alkylating chemical carcinogens such as NMU and NEU in human transfectant squamous cell carcinoma (SCC-13) cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1980 Nov;22(2 Pt 2):629-32 [6160916.001]
  • [Cites] Nature. 1985 May 30-Jun 5;315(6018):382-5 [3923365.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):285-98 [15134535.001]
  • [Cites] Biol Pharm Bull. 2003 Aug;26(8):1195-7 [12913277.001]
  • [Cites] J Surg Res. 2002 Apr;103(2):183-9 [11922733.001]
  • [Cites] J Neurosci Res. 2002 Mar 1;67(5):670-9 [11891779.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2001 Aug;23(3):335-42 [11694025.001]
  • [Cites] Anal Biochem. 2001 May 1;292(1):17-21 [11319812.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1085-9 [11007945.001]
  • [Cites] Cell Signal. 2006 Jun;18(6):889-98 [16176868.001]
  • [Cites] Radiat Res. 2005 Mar;163(3):296-306 [15733037.001]
  • [Cites] Adv Immunol. 1997;65:111-37 [9238509.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1081-5 [9067275.001]
  • [Cites] J Mol Med (Berl). 1996 Dec;74(12):749-69 [8974017.001]
  • [Cites] FASEB J. 1996 Jul;10(9):1031-9 [8801164.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):976-80 [7906199.001]
  • [Cites] Biochem Pharmacol. 1994 Jan 13;47(1):145-9 [8311838.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):4827-33 [3409223.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Nature. 1987 Dec 17-23;330(6149):624-9 [2825036.001]
  • [Cites] Nature. 1988 Jun 16;333(6174):669-72 [2836738.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):499-502 [3477106.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):829-33 [6848195.001]
  • (PMID = 19746216.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739321
  • [Keywords] NOTNLM ; Chemoprevention / Human keratinocytes / NEU / NF-κB / NMU / Retinoids
  •  go-up   go-down


15. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


16. Mathews WC, Cachay ER, Caperna J, Sitapati A, Cosman B, Abramson I: Estimating the accuracy of anal cytology in the presence of an imperfect reference standard. PLoS One; 2010 Aug 19;5(8):e12284
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimating the accuracy of anal cytology in the presence of an imperfect reference standard.
  • BACKGROUND: The study aim is to estimate sensitivity and specificity of anal cytology for histologic HSIL in analyses adjusted for the imperfect biopsy reference standard.
  • METHODS AND PRINCIPAL FINDINGS: Retrospective cohort study of an anal dysplasia screening program for HIV infected adults.
  • CONCLUSIONS: Analysis of a single dataset yields widely different estimates of anal cytology operating characteristics that depend on difficult to verify assumptions regarding the accuracy of the imperfect reference standard.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] AIDS. 2010 Jan 28;24(3):373-9 [20057313.001]
  • [Cites] Top HIV Med. 2003 Mar-Apr;11(2):45-9 [12717041.001]
  • [Cites] J Chronic Dis. 1981;34(12):599-610 [6458624.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3002-6 [8221568.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):269-79 [15386329.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]
  • [Cites] Epidemiology. 2005 Sep;16(5):604-12 [16135935.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):62-6 [16374220.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):253-6 [16445640.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Biostatistics. 2007 Apr;8(2):474-84 [17085745.001]
  • [Cites] Sex Transm Infect. 2008 Apr;84(2):94-6 [17881414.001]
  • [Cites] J Clin Epidemiol. 2009 Aug;62(8):797-806 [19447581.001]
  • [Cites] Curr Opin Infect Dis. 2010 Feb;23(1):21-5 [19935419.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • (PMID = 20808869.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI036214; United States / NIAID NIH HHS / AI / R24 AI067039; United States / NIAID NIH HHS / AI / AI 36214; United States / NIAID NIH HHS / AI / AI067039
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2924391
  •  go-up   go-down


17. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
  • PURPOSE: To assess survival, local control, and toxicity of intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the anal canal.
  • CONCLUSIONS: In this hypothesis-generating analysis, the acute toxicity and clinical outcome with IMRT in the treatment of anal cancer is encouraging.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168830.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh H, Hizawa N: Serum KL-6 levels in lung cancer patients with or without interstitial lung disease. J Clin Lab Anal; 2010;24(5):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum KL-6 levels in lung cancer patients with or without interstitial lung disease.
  • BACKGROUND: It is not known whether lung cancer patients with interstitial lung disease (ILD) might have higher serum levels of KL-6, a high molecular weight glycoprotein classified as a polymorphic epithelial mucin.
  • METHODS: Serum KL-6 levels in 273 lung cancer patients with or without ILD, and prognostic significance of elevated serum KL-6 levels in these patients were studied using uni- and multivariate analyses.
  • RESULTS: Serum KL-6 levels were elevated (>500 U/ml) in 73.5% of lung cancer patients with ILD and in 33.7% of those without ILD.
  • Serum KL-6 levels in lung cancer patients with ILD were significantly higher than those without ILD.
  • In lung cancer patients with ILD, elevated serum KL-6 has no prognostic significance, but in those without ILD, however, it was one of the unfavorable prognostic factors.
  • CONCLUSIONS: Elevated serum KL-6 levels can be observed in lung cancer patients both with and without ILD.
  • Having ILD has strong prognostic impact in patients with lung cancer.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoma, Large Cell / blood. Carcinoma, Small Cell / blood. Carcinoma, Squamous Cell / blood. Lung Diseases, Interstitial / blood. Lung Neoplasms / blood. Mucin-1 / blood


19. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg; 2007 Nov;11(11):1410-5; discussion 1415-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.
  • Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.
  • We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.
  • Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.
  • Progression to HSIL was seen in one patient with LSIL and to squamous cell carcinoma in one patient with HSIL despite therapy.
  • HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.
  • Morbidity is minimal, and our progression to cancer rate is low (2.4%).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):126 [16222485.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):259-61 [15006881.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1063-6 [10460644.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 17710507.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bean SM, Chhieng DC: Anal-rectal cytology: a review. Diagn Cytopathol; 2010 Jul;38(7):538-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal-rectal cytology: a review.
  • The incidence of invasive anal squamous cell carcinoma, a human papilloma virus (HPV) related cancer, is on the rise, especially in HIV positive men who have sex with men (MSM).
  • Like cervical cancer, anal cancer is associated with precursor lesions detectable on exfoliative cytology as squamous intraepithelial lesions and on biopsy as intraepithelial neoplasia.
  • Anal-rectal cytology screening programs, similar to cervical cytology screening programs, have been developed in an effort to detect and to eradicate precursor lesions prior to progression to invasive squamous cell carcinoma.
  • Either conventional or liquid-based anal-rectal cytology specimens are acceptable, but liquid-based specimens are preferred.
  • A minimum of 2,000-3,000 nucleate squamous cells should comprise adequate specimens.
  • Sensitivity and specificity of a single anal-rectal cytology specimen is comparable with that of a single cervical cytology test, but cytological interpretations do not always correlate with lesion severity.
  • Patients with atypical squamous cells of undetermined significance (ASC-US) or worse should be referred for anoscopy.
  • [MeSH-major] Anal Canal / pathology. Rectum / pathology
  • [MeSH-minor] Anus Neoplasms / diagnosis. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Early Detection of Cancer. Humans. Papillomaviridae / physiology. Specimen Handling

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19941374.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


22. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum; 2005 Jan;48(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer.
  • PURPOSE: Radiotherapy alone or with combined chemotherapy is the first therapeutic option for epidermoid carcinoma of the anal canal.
  • CONCLUSIONS: Despite high incidence of perineal morbidity, salvage abdominoperineal resection for epidermoid carcinomas of the anal canal has a high long-term survival rate.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690652.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lu XM, Yang T, Xu SY, Wen H, Wang X, Ren ZH, Zhang Y, Wang W: Glutathione-S-transferase M1 polymorphisms on the susceptibility to esophageal cancer among three Chinese minorities: Kazakh, Tajik and Uygur. World J Gastroenterol; 2006 Dec 28;12(48):7758-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione-S-transferase M1 polymorphisms on the susceptibility to esophageal cancer among three Chinese minorities: Kazakh, Tajik and Uygur.
  • Primary esophageal squamous cell cancer (ESCC) tissues from Kazakh were obtained from 116 patients who underwent surgery.
  • [MeSH-major] Esophageal Neoplasms / genetics. Genetic Predisposition to Disease / ethnology. Glutathione Transferase / genetics. Neoplasms, Squamous Cell / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):185-91 [10698480.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):205-8 [16098500.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24798-806 [10783391.001]
  • [Cites] Mutat Res. 2001 Oct 1;482(1-2):21-6 [11535245.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Am J Epidemiol. 2002 Jul 15;156(2):95-109 [12117698.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):113-8 [12925965.001]
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):S1367-9 [14530066.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 15;146(2):125-9 [14553946.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):193-9 [14643449.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):14-8 [15047208.001]
  • [Cites] World J Gastroenterol. 2004 Apr 1;10(7):940-4 [15052670.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1287-91 [15194507.001]
  • [Cites] Cancer Lett. 2004 Sep 30;213(2):195-202 [15327835.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Biochem J. 1994 May 15;300 ( Pt 1):271-6 [8198545.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):176-81 [15668493.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):736-40 [15721419.001]
  • [Cites] Mutat Res. 2005 Mar 7;581(1-2):153-63 [15725614.001]
  • [Cites] World J Gastroenterol. 2005 May 7;11(17):2531-8 [15849806.001]
  • [Cites] Eur J Cancer. 2005 May;41(7):980-9 [15862746.001]
  • [Cites] Eur J Cancer Prev. 2005 Jun;14(3):281-4 [15901999.001]
  • [Cites] Mutat Res. 2005 Jul 1;574(1-2):112-23 [15914211.001]
  • [Cites] Drug Metab Rev. 2005;37(2):327-78 [15931768.001]
  • [Cites] World J Gastroenterol. 2005 Jun 28;11(24):3651-4 [15968714.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):649-59 [16112301.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):551-6 [10868687.001]
  • (PMID = 17203516.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  • [Other-IDs] NLM/ PMC4087538
  •  go-up   go-down


24. Gupta A, Bhatt ML, Misra MK: Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev; 2009 Apr-Jun;2(2):68-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients.
  • Oxidative stress, a consequence of an imbalance between the formation and inactivation of reactive oxygen species, may be involved in the pathogenesis of many diseases including cancer.
  • To evaluate the magnitude of oxidative stress, a study on the plasma levels of superoxide dismutase, total thiols, ascorbic acid and malondialdehyde (MDA) has been done in head and neck squamous cell carcinoma patients before the start of any oncological treatment and compared with healthy controls.
  • The specific activity of superoxide dismutase in cancer patients is decreased significantly when compared to the control (p < 0.05).
  • Our findings show that the oxidative stress is elevated in cancer patients as evidenced by elevated levels of lipid peroxidation products and depletion of enzymatic and non-enzymatic antioxidants.
  • [MeSH-major] Antioxidants / metabolism. Carcinoma, Squamous Cell / metabolism. Head and Neck Neoplasms / metabolism. Lipid Peroxidation

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):15-8 [10766417.001]
  • [Cites] Proc Soc Exp Biol Med. 1991 Nov;198(2):675-82 [1656469.001]
  • [Cites] Clin Biochem. 2002 Nov;35(8):621-5 [12498996.001]
  • [Cites] Free Radic Res. 2003 Mar;37(3):231-40 [12688418.001]
  • [Cites] Exp Biol Med (Maywood). 2003 May;228(5):525-8 [12709580.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jul;34(7):379-85 [15342664.001]
  • [Cites] J Biol Chem. 1972 May 25;247(10):3170-5 [4623845.001]
  • [Cites] Biochem J. 1974 Apr;139(1):43-8 [4377099.001]
  • [Cites] J Biol Chem. 1978 Nov 25;253(22):8143-8 [213429.001]
  • [Cites] Methods Enzymol. 1979;62:3-11 [440112.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] J Supramol Struct Cell Biochem. 1981;17(2):133-46 [7033553.001]
  • [Cites] Mutat Res. 1987 Jul;186(1):43-72 [3299074.001]
  • [Cites] Arch Biochem Biophys. 1990 Jul;280(1):1-8 [2191627.001]
  • [Cites] Free Radic Biol Med. 1990;8(6):583-99 [2193855.001]
  • [Cites] Free Radic Biol Med. 1991;10(3-4):201-9 [1864525.001]
  • [Cites] Lancet. 1994 Sep 24;344(8926):862-3 [7916406.001]
  • [Cites] Carcinogenesis. 1998 Jul;19(7):1275-83 [9683189.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Jun;24(3):232-4 [10384852.001]
  • [Cites] Head Neck. 1999 Aug;21(5):467-79 [10402529.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6 Suppl):1113S-1118S [1962556.001]
  • [Cites] Br Med Bull. 1993 Jul;49(3):523-44 [8221020.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jan;59(2):163-70 [10817351.001]
  • [Cites] Clin Biochem. 1999 Jul;32(5):369-73 [10480452.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Toxicol Environ Health A. 2005 Sep;68(17-18):1511-23 [16076763.001]
  • [Cites] Methods Enzymol. 1994;233:380-5 [8015473.001]
  • (PMID = 20357927.001).
  • [ISSN] 1942-0994
  • [Journal-full-title] Oxidative medicine and cellular longevity
  • [ISO-abbreviation] Oxid Med Cell Longev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Sulfhydryl Compounds; 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase; PQ6CK8PD0R / Ascorbic Acid
  • [Other-IDs] NLM/ PMC2763247
  • [Keywords] NOTNLM ; ascorbic acid / head and neck cancer / lipid peroxidation / oxidative stress / superoxide dismutase / total thiols
  •  go-up   go-down


25. Bell I, Martin A, Roberts S: The E1circumflexE4 protein of human papillomavirus interacts with the serine-arginine-specific protein kinase SRPK1. J Virol; 2007 Jun;81(11):5437-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomavirus (HPV) infections of the squamous epithelium are associated with high-level expression of the E1circumflexE4 protein during the productive phase of infection.
  • SRPK1 influences important biochemical processes within the cell, including nuclear organization and RNA metabolism.
  • [MeSH-minor] Amino Acid Sequence. Arginine / metabolism. Cell Line. Human papillomavirus 16 / genetics. Human papillomavirus 16 / metabolism. Human papillomavirus 18 / genetics. Human papillomavirus 18 / metabolism. Humans. Keratinocytes / enzymology. Keratinocytes / virology. Molecular Sequence Data. Phosphorylation. Serine / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Mar 1;28(5):E14 [10666475.001]
  • [Cites] Front Biosci. 2006;11:2286-302 [16720315.001]
  • [Cites] J Virol. 2000 Nov;74(21):10081-95 [11024137.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):899-905 [11336712.001]
  • [Cites] Eur J Biochem. 2002 Feb;269(3):943-53 [11846796.001]
  • [Cites] J Virol. 2002 Oct;76(19):9806-18 [12208959.001]
  • [Cites] J Virol. 2002 Oct;76(20):10401-16 [12239317.001]
  • [Cites] J Virol. 2002 Nov;76(21):10914-20 [12368334.001]
  • [Cites] EMBO Rep. 2002 Nov;3(11):1088-93 [12393754.001]
  • [Cites] J Virol. 2003 Jan;77(1):673-84 [12477870.001]
  • [Cites] EMBO J. 2003 Apr 1;22(7):1608-19 [12660167.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4139-49 [12773558.001]
  • [Cites] J Virol. 2004 Jan;78(2):821-33 [14694114.001]
  • [Cites] J Virol. 2004 Feb;78(4):2142-51 [14747580.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):13265-71 [14718546.001]
  • [Cites] Genes Dev. 2004 Apr 1;18(7):755-68 [15082528.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] J Virol. 2006 Aug;80(15):7416-26 [16840322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33 [16840555.001]
  • [Cites] Virology. 2006 Aug 1;351(2):271-9 [16687161.001]
  • [Cites] Virology. 2007 Jun 5;362(2):453-60 [17303206.001]
  • [Cites] J Virol. 2004 Jul;78(13):7199-207 [15194796.001]
  • [Cites] J Virol. 2004 Oct;78(19):10598-605 [15367627.001]
  • [Cites] J Virol. 2004 Oct;78(20):10888-905 [15452209.001]
  • [Cites] EMBO J. 1988 Mar;7(3):825-33 [2456213.001]
  • [Cites] Virology. 1989 May;170(1):201-13 [2470193.001]
  • [Cites] Virology. 1989 Sep;172(1):51-62 [2549722.001]
  • [Cites] Nature. 1991 Aug 29;352(6338):824-7 [1715519.001]
  • [Cites] Anal Chem. 1991 Dec 15;63(24):1193A-1203A [1789447.001]
  • [Cites] EMBO J. 1992 Nov;11(11):4027-36 [1327755.001]
  • [Cites] Virology. 1993 Nov;197(1):176-87 [8212552.001]
  • [Cites] J Invest Dermatol. 1993 Dec;101(6):843-51 [7504028.001]
  • [Cites] J Virol. 1994 Oct;68(10):6432-45 [7521917.001]
  • [Cites] RNA. 1995 Sep;1(7):663-80 [7585252.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6208-13 [9045635.001]
  • [Cites] J Virol. 1997 May;71(5):3554-62 [9094627.001]
  • [Cites] Genes Dev. 1998 Jan 1;12(1):55-66 [9420331.001]
  • [Cites] Virology. 1998 Jan 20;240(2):221-31 [9454695.001]
  • [Cites] Nature. 1998 May 14;393(6681):185-7 [9603524.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6359-67 [9799243.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):165-9 [9883877.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):602-7 [10049757.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):11125-31 [10196197.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11832-41 [10207001.001]
  • [Cites] J Virol. 2004 Dec;78(24):13920-33 [15564500.001]
  • [Cites] Mol Cell. 2005 Mar 4;17(5):613-5 [15749011.001]
  • [Cites] J Virol. 2005 Apr;79(7):3998-4011 [15767402.001]
  • [Cites] EMBO Rep. 2005 May;6(5):452-7 [15864296.001]
  • [Cites] J Virol. 2005 Jun;79(11):6732-40 [15890911.001]
  • [Cites] Retrovirology. 2005;2:33 [15907217.001]
  • [Cites] J Virol. 2005 Sep;79(18):12002-15 [16140776.001]
  • [Cites] J Virol. 2005 Oct;79(20):13150-65 [16189016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15042-7 [16210245.001]
  • [Cites] Mol Cell. 2005 Nov 11;20(3):413-25 [16285923.001]
  • [Cites] Virology. 2006 Feb 5;345(1):290-8 [16257432.001]
  • [Cites] Mol Biol Cell. 2006 Feb;17(2):876-85 [16319169.001]
  • [Cites] Rev Med Virol. 2006 Mar-Apr;16(2):83-97 [16287204.001]
  • [Cites] Virology. 2006 May 25;349(1):230-44 [16540140.001]
  • [Cites] Virology. 2000 Mar 15;268(2):430-9 [10704351.001]
  • (PMID = 17360743.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E1 protein, human papillomavirus type 1; 0 / Oncogene Proteins, Viral; 0 / Viral Proteins; 0 / oncogene protein E4, Human papillomavirus type 16; 0 / oncogene protein E4, human papilloma virus type 1; 452VLY9402 / Serine; 94ZLA3W45F / Arginine; EC 2.7.1.- / SRPK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1900295
  •  go-up   go-down


26. Raica M, Cimpean AM, Ribatti D: Angiogenesis in pre-malignant conditions. Eur J Cancer; 2009 Jul;45(11):1924-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MVD was found to be significantly increased in a relatively large spectrum of pre-malignant squamous cell lesions, such as in the oral mucosa, skin, uterine cervix, vulva and anal canal.

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406633.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 93
  •  go-up   go-down


27. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS: Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer; 2007;7:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have explored this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not influenced by other histopathological parameters like tumor load and tumor cell density.
  • Apoptotic cell density, tumor cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition.
  • RESULTS: The apoptotic cell density correlated with the standard pulse-acquire spectra (p < 0.001), but not with the spin-echo spectra, showing that the lipid metabolites were most important.
  • In contrast, the spin-echo spectra contained the main information on tumor cell fraction and tumor cell density (p < 0.001), for which cholines, creatine, taurine, glucose, and lactate were most important.
  • Significant correlations were found between tumor cell fraction and glucose concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC) concentration (p = 0.024) and ratio of GPC to choline (p < 0.001).
  • These changes differed from those associated with tumor load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in the course of the disease.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Spectroscopy / methods. Uterine Cervical Neoplasms / pathology


28. Wang TD, Triadafilopoulos G, Crawford JM, Dixon LR, Bhandari T, Sahbaie P, Friedland S, Soetikno R, Contag CH: Detection of endogenous biomolecules in Barrett's esophagus by Fourier transform infrared spectroscopy. Proc Natl Acad Sci U S A; 2007 Oct 2;104(40):15864-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, spectra were collected from 98 excised specimens of the distal esophagus, including 38 squamous, 38 intestinal metaplasia (Barrett's), and 22 gastric, obtained endoscopically from 32 patients.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Jul;72(1):146-50 [10911740.001]
  • [Cites] Am J Vet Res. 2007 May;68(5):517-23 [17472451.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Anal Biochem. 2000 Dec 15;287(2):218-25 [11112267.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Biomacromolecules. 2003 Sep-Oct;4(5):1184-90 [12959582.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):558-67 [15189094.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):868-79 [15476150.001]
  • [Cites] Science. 1976 Jan 9;191(4222):31-7 [1246596.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(20):8140-4 [2236027.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):10988-92 [1763013.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):169-74 [8008738.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Biospectroscopy. 1998;4(1):47-53 [9547014.001]
  • [Cites] Clin Chem. 2005 Feb;51(2):346-50 [15637129.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):269-74 [15791571.001]
  • [Cites] Annu Rev Phys Chem. 2005;56:429-74 [15796707.001]
  • [Cites] Nat Biotechnol. 2005 Apr;23(4):469-74 [15793574.001]
  • [Cites] Biophys J. 2006 May 15;90(10):3783-95 [16500983.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1460-4 [16622450.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):E1 [18079288.001]
  • (PMID = 17901200.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067618; United States / NIDDK NIH HHS / DK / R01 DK063624; United States / NCI NIH HHS / CA / U54 CA105296; United States / NIDDK NIH HHS / DK / K08 DK67618
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2000401
  •  go-up   go-down


29. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer; 2005 Oct 1;104(7):1505-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer incidence rates were race specific and were adjusted for age; these were compared with national rates using logistic regression to assess predictors of NADC development.
  • The most frequent NADCs were skin carcinomas (basal cell and squamous cell), Hodgkin disease, and anal carcinoma.
  • The results showed that there were higher rates of melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease among the HIV-infected cohort compared with age-adjusted rates for the general United States population.
  • Melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease occurred at higher rates among HIV-infected individuals.


30. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI: HIV infection and the risk of cancers with and without a known infectious cause. AIDS; 2009 Nov 13;23(17):2337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident AIDS-defining cancers (ADCs), infection-related non-AIDS-defining cancers (NADCs; anal squamous cell, vagina/vulva, Hodgkin's lymphoma, penis, liver, human papillomavirus-related oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).
  • These results were largely influenced by anal squamous cell cancer and Hodgkin's lymphoma.
  • Among infection-unrelated NADCs, other anal, skin, other head and neck, and lung cancer rates were higher and prostate cancer rates lower in HIV-infected persons.
  • Among all infection-unrelated NADCs, the rate ratio decreased over time only for lung cancer (P = 0.007).


32. Taylor WE, Wolff BG, Pemberton JH, Yaszemski MJ: Sacral osteomyelitis after ileal pouch-anal anastomosis: report of four cases. Dis Colon Rectum; 2006 Jun;49(6):913-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacral osteomyelitis after ileal pouch-anal anastomosis: report of four cases.
  • PURPOSE: This study describes an institutional experience with sacral osteomyelitis after proctocolectomy and ileal pouch-anal anastomosis.
  • METHODS: A total of 2,375 patients underwent ileal pouch-anal anastomosis at the Mayo Clinic between January 1981 and January 2002.
  • In addition, we have served as a tertiary referral base for patients with complications after ileal pouch-anal anastomosis performed at other institutions.
  • Review of our ileal pouch-anal anastomosis prospective database and directed search of the central pathology, microbiology, radiology, and surgical records at the Mayo Clinic was performed using these keywords: osteomyelitis, ileal pouch-anal anastomosis, inflammatory bowel disease, chronic ulcerative colitis, and Crohn's disease.
  • RESULTS: Two of 2,375 patients (0.08 percent) with ileal pouch-anal anastomosis performed at our institution have had sacral osteomyelitis.
  • In addition, two patients have been referred for continuing care after construction of an ileal pouch-anal anastomosis and diagnosis of sacral osteomyelitis at another institution.
  • The last patient died from squamous-cell cancer involving the sacrum.
  • CONCLUSIONS: Sacral osteomyelitis is a rare and heretofore unreported complication of ileal pouch-anal anastomosis.
  • Conservative measures using antibiotics alone proved unsuccessful, and delaying definitive management may have contributed to the degeneration of a chronic sacral abscess into squamous-cell cancer.
  • [MeSH-minor] Adolescent. Adult. Anal Canal / surgery. Anastomosis, Surgical / adverse effects. Humans. Male

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741645.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


34. Patel HS, Silver AR, Levine T, Williams G, Northover JM: Human papillomavirus infection and anal dysplasia in renal transplant recipients. Br J Surg; 2010 Nov;97(11):1716-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection and anal dysplasia in renal transplant recipients.
  • BACKGROUND: Immunosuppression is a known risk factor for anal human papillomavirus (HPV) disease, including anal squamous cell carcinoma.
  • The demographics of anal HPV and associated risk factors were investigated in this population.
  • METHODS: Anal cytology and polymerase chain reaction were used to assess anal HPV disease in a cohort of transplant recipients at the Royal London Hospital.
  • Risk factors associated with increased immunosuppression and HPV exposure were collated to determine any association with anal disease.
  • RESULTS: Anal dysplasia was associated with anal oncogenic HPV infection (P < 0.001), duration of immunosuppression (P = 0.050), previous genital warts (P = 0.018) and receptive anal intercourse (P = 0.013).
  • CONCLUSION: Anal dysplasia was related to immunosuppression and patient factors in this cohort.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Immunosuppression / adverse effects. Kidney Transplantation. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Renal dysplasia.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20730855.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


35. Marwitz S, Zeiser T, Schultz H, Kähler D, Abdullah M, Hauber HP, Zabel P, Vollmer E, Goldmann T: The human placenta releases substances that drive lung cancer into apoptosis. Diagn Pathol; 2009;4:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human placenta releases substances that drive lung cancer into apoptosis.
  • BACKGROUND: As there is no optimal treatment of non small cell lung cancer due to its resistance to common chemotherapeutics, we investigated the effect of human placenta-conditioned medium on tumor tissue.
  • METHODS: Freshly resected non small cell lung cancer tissues were incubated with placenta-conditioned medium in a short-term tissue culture model and A549 cells were challenged, respectively.
  • The effects of conditioned medium on squamous cell carcinoma were further compared to physiological concentrations of Carboplat/Gemzar.
  • In cell culture up to 50% of karyopyknosis was investigated and even sterile-filtrated medium caused widespread reduction of Ki67 on protein level.
  • CONCLUSION: Human placenta releases substances that mediate apoptosis and reduce proliferation in tumor tissue and cell culture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Pathol. 2008;3:35 [18700018.001]
  • [Cites] Respir Res. 2007;8:43 [17567922.001]
  • [Cites] Diagn Pathol. 2007;2:8 [17326824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5478-83 [16567644.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Feb;28(1):27-38 [16566277.001]
  • [Cites] Placenta. 1998 Sep;19(7):457-64 [9778118.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(3):192-6 [2033088.001]
  • [Cites] Di Yi Jun Yi Da Xue Xue Bao. 2004 Jul;24(7):752-5 [15257893.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Mar 25;2:15 [15043753.001]
  • [Cites] Placenta. 2001 Sep-Oct;22(8-9):663-72 [11597186.001]
  • (PMID = 19698096.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2733300
  •  go-up   go-down


36. Murrell ZA, Dixon MR, Vargas H, Arnell TD, Kumar R, Stamos MJ: Contemporary indications for and early outcomes of abdominoperineal resection. Am Surg; 2005 Oct;71(10):837-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for operation were primary rectal cancer (n = 31), recurrent rectal cancer (n = 6), intractable Crohn disease (n = 3), anal melanoma (n = 1), cloacogenic cancer (n = 1), squamous cell cancer (n = 1), and gastrointestinal stromal tumor (n = 1).
  • Despite the significant morbidity associated with this surgery, APR may provide beneficial treatment for select cases of low rectal cancer, end-stage inflammatory bowel disease, and anal malignancies.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468531.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Zheng ZM, Baker CC: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci; 2006 Sep 01;11:2286-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Certain types of HPVs, such as HPV-16, HPV-18, and HPV-31, have been recognized as causative agents of cervical cancer and anal cancer and their infections, which arise via sexual transmission, are associated with more than 95% of cervical cancer.
  • Papillomaviruses infect keratinocytes in the basal layer of stratified squamous epithelia and replicate in the nucleus of infected keratinocytes in a differentiation-dependent manner.
  • Viral gene expression in infected cells depends on cell differentiation and is tightly regulated at the transcriptional and post-transcriptional levels.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1986 Sep;5(9):2285-92 [3023067.001]
  • [Cites] J Virol. 1987 Jan;61(1):134-42 [3023691.001]
  • [Cites] Nature. 1987 Jan 1-7;325(6099):70-3 [3025749.001]
  • [Cites] Cell. 1987 Jul 3;50(1):69-78 [3036366.001]
  • [Cites] EMBO J. 1988 Feb;7(2):525-31 [2835231.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3780-6 [2837324.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(16):5864-8 [2842752.001]
  • [Cites] J Virol. 1989 Mar;63(3):1441-7 [2536845.001]
  • [Cites] J Virol. 1989 Apr;63(4):1743-55 [2538655.001]
  • [Cites] J Virol. 1989 Aug;63(8):3529-34 [2545923.001]
  • [Cites] Virology. 1989 Sep;172(1):331-40 [2549716.001]
  • [Cites] J Virol. 1990 Apr;64(4):1825-9 [2157064.001]
  • [Cites] J Virol. 1990 Jun;64(6):2849-59 [2159546.001]
  • [Cites] Biochim Biophys Acta. 1990 Jun 1;1032(1):19-37 [2163676.001]
  • [Cites] Virology. 1990 Sep;178(1):254-62 [2167553.001]
  • [Cites] J Virol. 1991 Apr;65(4):2093-7 [1848319.001]
  • [Cites] J Virol. 1991 Sep;65(9):4860-6 [1651408.001]
  • [Cites] J Virol. 1991 Nov;65(11):5806-12 [1717710.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):356-64 [1310488.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]
  • [Cites] J Virol. 1992 Oct;66(10):6070-80 [1326657.001]
  • [Cites] Virology. 1992 Dec;191(2):953-9 [1333130.001]
  • [Cites] Biochem Mol Biol Int. 1998 Aug;45(5):1005-9 [9739465.001]
  • [Cites] Nucleic Acids Res. 1998 Dec 1;26(23):5237-42 [9826743.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):113-25 [10594014.001]
  • [Cites] J Virol. 2000 Feb;74(3):1178-86 [10627528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4677-82 [10781073.001]
  • [Cites] J Virol. 2000 Jul;74(13):5902-10 [10846071.001]
  • [Cites] J Virol. 2000 Aug;74(16):7284-97 [10906182.001]
  • [Cites] J Virol. 2000 Nov;74(22):10612-22 [11044105.001]
  • [Cites] J Virol. 2001 May;75(9):4139-49 [11287563.001]
  • [Cites] J Virol. 2001 Sep;75(17):8147-57 [11483760.001]
  • [Cites] J Virol. 2001 Oct;75(19):9201-9 [11533183.001]
  • [Cites] J Virol. 2002 Mar;76(5):2263-73 [11836404.001]
  • [Cites] J Virol. 2002 Mar;76(6):2739-52 [11861841.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 15;30(8):1842-50 [11937639.001]
  • [Cites] J Virol. 2002 Jun;76(12):5993-6003 [12021332.001]
  • [Cites] J Virol. 2002 Jul;76(14):7040-8 [12072504.001]
  • [Cites] J Mol Biol. 2002 May 17;318(5):1189-206 [12083511.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6041-8 [12203116.001]
  • [Cites] Virology. 2002 Sep 15;301(1):43-52 [12359445.001]
  • [Cites] J Virol. 2002 Nov;76(22):11291-300 [12388689.001]
  • [Cites] Genome Biol. 2002 Oct 23;3(11):reviews0008 [12429065.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):765-77 [15868908.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):257-61 [15901494.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):143-51 [15905729.001]
  • [Cites] Biochem Soc Trans. 2005 Jun;33(Pt 3):443-6 [15916537.001]
  • [Cites] J Virol. 2005 Jul;79(14):9254-69 [15994820.001]
  • [Cites] J Virol. 2005 Sep;79(18):12002-15 [16140776.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6544-9 [16166431.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8643-55 [16166644.001]
  • [Cites] Gene Ther. 2005 Oct;12(20):1477-85 [16121205.001]
  • [Cites] Development. 2005 Nov;132(21):4653-62 [16224045.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9595-607 [16227608.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2094-104 [16369495.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):371-8 [15372045.001]
  • [Cites] J Virol. 2004 Oct;78(20):10888-905 [15452209.001]
  • [Cites] J Virol. 2004 Oct;78(20):11172-86 [15452237.001]
  • [Cites] Eur J Biochem. 1980 Aug;109(2):457-61 [6250842.001]
  • [Cites] Nature. 1982 Oct 7;299(5883):529-34 [6289124.001]
  • [Cites] Virology. 1983 Apr 30;126(2):493-504 [6305000.001]
  • [Cites] EMBO J. 1982;1(2):231-6 [6325156.001]
  • [Cites] Nucleic Acids Res. 1984 Dec 11;12(23):8847-60 [6096809.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] J Virol. 2003 Feb;77(3):2021-8 [12525636.001]
  • [Cites] J Virol. 2003 Feb;77(3):2105-15 [12525645.001]
  • [Cites] Antivir Ther. 2002 Dec;7(4):219-37 [12553476.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Virol. 2003 Apr;77(8):4928-37 [12663798.001]
  • [Cites] J Virol. 2003 May;77(9):5167-77 [12692219.001]
  • [Cites] J Virol. 2003 May;77(10):6066-9 [12719599.001]
  • [Cites] J Virol. 2003 Jun;77(11):6227-34 [12743279.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):111-6 [12807954.001]
  • [Cites] Virology. 2003 Jun 20;311(1):105-14 [12832208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8264-9 [12826613.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5938-45 [12955072.001]
  • [Cites] J Virol. 2003 Oct;77(19):10186-201 [12970404.001]
  • [Cites] J Virol. 2003 Oct;77(19):10213-26 [12970406.001]
  • [Cites] J Virol. 2003 Nov;77(21):11674-84 [14557653.001]
  • [Cites] J Gen Virol. 2003 Nov;84(Pt 11):2909-20 [14573795.001]
  • [Cites] J Virol. 2003 Dec;77(23):12450-9 [14610169.001]
  • [Cites] Virus Res. 2003 Dec;98(2):95-104 [14659556.001]
  • [Cites] J Virol. 2004 Jan;78(2):612-29 [14694093.001]
  • [Cites] EMBO J. 2004 Feb 11;23(3):616-26 [14749727.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4680-4 [3014503.001]
  • [Cites] J Virol. 2004 Mar;78(5):2609-14 [14963167.001]
  • [Cites] Nat Rev Microbiol. 2004 Apr;2(4):343-7 [15031733.001]
  • [Cites] RNA. 2004 Apr;10(4):565-73 [15037765.001]
  • [Cites] J Mol Biol. 2004 Apr 9;337(5):1091-108 [15046980.001]
  • [Cites] J Biomed Sci. 2004 May-Jun;11(3):278-94 [15067211.001]
  • [Cites] J Gen Virol. 2004 Jun;85(Pt 6):1433-44 [15166426.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Virology. 2004 Jul 1;324(2):483-92 [15207633.001]
  • [Cites] Virology. 2004 Aug 15;326(1):57-66 [15262495.001]
  • [Cites] Gene Ther. 2004 Sep;11(17):1331-41 [15229628.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4448-61 [15319446.001]
  • [Cites] J Virol. 2004 Oct;78(19):10598-605 [15367627.001]
  • [Cites] FEBS Lett. 1993 May 3;322(1):21-4 [8387026.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):833-9 [8387290.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2330-7 [7683572.001]
  • [Cites] J Gen Virol. 1993 May;74 ( Pt 5):791-801 [8388016.001]
  • [Cites] J Virol. 1993 Sep;67(9):5605-16 [8394463.001]
  • [Cites] J Virol. 1993 Dec;67(12):7705-10 [7901430.001]
  • [Cites] J Biol Chem. 1994 Apr 22;269(16):11902-11 [8163489.001]
  • [Cites] Proc Natl Sci Counc Repub China B. 1993 Oct;17(4):159-63 [8171167.001]
  • [Cites] Mol Cell Biol. 1994 Aug;14(8):5278-89 [8035806.001]
  • [Cites] J Virol. 1994 Oct;68(10):6567-77 [8083993.001]
  • [Cites] J Virol. 1995 May;69(5):2932-45 [7707519.001]
  • [Cites] J Virol. 1995 Jun;69(6):3381-8 [7745684.001]
  • [Cites] Cancer Gene Ther. 1994 Dec;1(4):267-77 [7627817.001]
  • [Cites] J Virol. 1995 Sep;69(9):5607-20 [7637007.001]
  • [Cites] Nucleic Acids Res. 1995 Jul 25;23(14):2614-20 [7651822.001]
  • [Cites] J Virol. 1995 Oct;69(10):6553-6 [7666558.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4599-605 [7553636.001]
  • [Cites] Cancer Gene Ther. 1995 Dec;2(4):263-71 [8548580.001]
  • [Cites] J Virol. 1996 Apr;70(4):2339-49 [8642661.001]
  • [Cites] J Virol. 1996 Jun;70(6):3355-62 [8648665.001]
  • [Cites] J Virol. 1996 Jul;70(7):4691-9 [8676495.001]
  • [Cites] J Virol. 1996 Oct;70(10):7233-5 [8794373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):163-8 [8990179.001]
  • [Cites] J Virol. 1997 Jul;71(7):5161-72 [9188583.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3993-9 [9307284.001]
  • [Cites] J Virol. 1997 Dec;71(12):9096-107 [9371566.001]
  • [Cites] Oncogene. 1997 Nov 6;15(19):2303-19 [9393875.001]
  • [Cites] J Virol. 1998 Feb;72(2):1504-15 [9445054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1189-94 [9448307.001]
  • [Cites] Mol Cell. 1998 Jan;1(2):255-64 [9659922.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22648-56 [9712894.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):1109-15 [12440984.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14088-93 [9826658.001]
  • [Cites] Virology. 1998 Nov 25;251(2):253-63 [9837789.001]
  • [Cites] J Virol. 1999 Jan;73(1):29-36 [9847303.001]
  • [Cites] J Virol. 1999 Apr;73(4):3062-70 [10074156.001]
  • [Cites] J Virol. 1999 Apr;73(4):3505-10 [10074210.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11832-41 [10207001.001]
  • [Cites] J Virol. 1999 Jun;73(6):4972-82 [10233959.001]
  • [Cites] J Virol. 1999 Sep;73(9):7185-92 [10438805.001]
  • [Cites] Gene Ther. 1999 Jun;6(6):1114-9 [10455414.001]
  • [Cites] J Virol. 2004 Dec;78(23):12762-72 [15542628.001]
  • [Cites] J Virol. 2004 Dec;78(23):12901-9 [15542642.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] J Virol. 2005 Mar;79(6):3309-21 [15731225.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S34-42 [15753010.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S43-51 [15753011.001]
  • [Cites] J Virol. 2005 Apr;79(7):4270-88 [15767428.001]
  • [Cites] J Virol. 2005 Apr;79(8):4918-26 [15795277.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):271-8 [15863374.001]
  • (PMID = 16720315.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC010357-06; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 152
  • [Other-IDs] NLM/ NIHMS8367; NLM/ PMC1472295
  •  go-up   go-down


38. Cummings BJ: Metastatic anal cancer: the search for cure. Onkologie; 2006 Feb;29(1-2):5-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic anal cancer: the search for cure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy


39. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J: Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol; 2009 Sep;114(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario.
  • OBJECTIVE: The oncogenic HPV subtypes responsible for gynecologic malignancies have also been implicated in the development of squamous cell cancer of the anus (SCAC).
  • The aim of this study was determine whether women diagnosed with anal cancer are more likely to have a history of HPV-related gynecological cancer as compared to a matched control group.
  • The exposure of interest was previous HPV-related gynecologic cancer, specifically cervical cancer, vulvar cancer and vaginal cancer.
  • Previous HPV-related gynecological cancer (cervical, vaginal or vulvar cancer) was significantly associated with SCAC (OR: 10.5, 95% C.I.: 3.6 to 30.3).
  • The median time between the diagnosis of anal cancer and previous cervical cancer was 20 years.
  • CONCLUSIONS: Previous HPV-related gynecological cancers are strongly associated with anal cancer and may occur decades before the anal cancer.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Genital Neoplasms, Female / epidemiology. Neoplasms, Multiple Primary / epidemiology. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501390.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.


41. Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, Collette L, Bosset JF, EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups: Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer; 2009 Nov;45(16):2782-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
  • PURPOSE: To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19643599.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00068744
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-31
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Moreau MV, Tournier-Rangeard L, Kaminsky MC, Peiffert D: [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer]. Cancer Radiother; 2009 Jul;13(4):329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer].
  • [Transliterated title] Chimioradiothérapie de rattrapage pour métastases médiastinales et pleuropulmonaires d'un cancer du canal anal.
  • This case report presents a 57 years-old woman treated for a squamous cell carcinoma of the anal canal by radiochemotherapy and brachytherapy.
  • This observation is interesting for its curative treatment in metastatic cancer of the anal canal.
  • It also illustrates the radiosensibility of anal canal cancers, including metastatic situations, and raises the contribution of PET-scanner to evaluate the response to treatment and detect a recurrence.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell / secondary. Mediastinal Neoplasms / secondary. Pleural Neoplasms / secondary. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467897.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Sahai A, Kodner IJ: Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg; 2006 May;19(2):88-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.
  • Premalignant and malignant lesions of the anal margin are rare.
  • Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]
  • [Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]
  • [Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]
  • (PMID = 20011315.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780101
  • [Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer
  •  go-up   go-down


44. Scott H, Khoury J, Moore BA, Weissman S: Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. Sex Transm Dis; 2008 Feb;35(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic.
  • OBJECTIVES: The purpose of this study is to describe our experience with routine anal cancer screening using anal cytology, determine risk factors for abnormal anal cytology, and determine if an association exists between cytology and histology in patients with HIV infection.
  • METHODS: Demographics, CD4+ T-cell count, STD history, and cytology and histology data were extracted from medical charts of patients seen between November 1, 2002, and November 30, 2004.
  • Multivariate analysis was conducted using logistic regression controlling for age, race, sex, CD4+ T-cell nadir, and HIV exposure category.
  • RESULTS: Overall, 276 of 560 of the clinic patients received a screening anal cytology during the study period.
  • Of these patients, 11 were excluded from the analysis and 74 of 265 (27.9%) patients screened had an abnormal anal cytology.
  • They were also more likely to have a lower CD4+ nadir (142 cells/mm3 vs. 223 cells/mm3, P = 0.005) and CD4+ at time of anal cytology (353 cells/mm3 vs. 497 cells/mm3, P <0.001).
  • Those with an abnormal anal cytology also had higher occurrence of anal disease on perianal visual inspection (30% vs. 9%, P <0.001) and were more likely to have a history of genital warts (23% vs. 12%, P = 0.02) or herpes (35% vs. 22%, P = 0.02).
  • Two patients had anal intraepithelial neoplasia (AIN) I, 2 AIN II, 3 AIN III, and 2 squamous cell carcinoma in situ on histology.
  • CONCLUSION: Routine anal cytology screening is a feasible tool to incorporate into HIV care for patients regardless of gender and HIV risk factors.
  • [MeSH-major] Anus Neoplasms / diagnosis. HIV Infections / complications. Neoplasms, Squamous Cell / pathology. Urban Health Services / organization & administration
  • [MeSH-minor] Adult. Aged. Anal Canal / pathology. Colonoscopy / methods. Female. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis


45. Yang P, Sun Z, Chan D, Cartwright CA, Vijjeswarapu M, Ding J, Chen X, Newman RA: Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis; 2008 Nov;29(11):2182-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we examined the effect of Zyflamend, a product containing 10 concentrated herbal extracts, on development of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced inflammation and oral squamous cell carcinoma (SCC).
  • The effect of Zyflamend on inhibition of LTB(4) formation was further confirmed with in vitro cell-based assay.
  • Adding LTB(4) to RBL-1 cells, a rat leukemia cell line expressing high levels of 5-LOX and LTA(4) hydrolase, partially blocked antiproliferative effect of Zyflamend.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cricetinae. Disease Models, Animal. Rats

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dent Res. 1961 Jan-Feb;40:3-15 [13772812.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):112-9 [10211319.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):2089-96 [15756036.001]
  • [Cites] In Vivo. 2005 Jan-Feb;19(1):247-52 [15796182.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):865-75 [15956244.001]
  • [Cites] Nutr Cancer. 2005;52(2):202-12 [16201851.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):81-5 [16430737.001]
  • [Cites] Biol Chem. 2006 Apr;387(4):365-72 [16606333.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1902-8 [16632477.001]
  • [Cites] Am J Epidemiol. 2006 Sep 15;164(6):556-66 [16847039.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1842-5 [17003715.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):385-95 [17011176.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):228-36 [17218785.001]
  • [Cites] Nutr Cancer. 2007;57(1):78-87 [17516865.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Biochem Suppl. 1993;17F:83-90 [8412211.001]
  • [Cites] Oral Oncol. 2000 Mar;36(2):221-4 [10745176.001]
  • [Cites] Anal Biochem. 2001 Oct 15;297(2):183-90 [11673886.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1307-13 [12151348.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Aug;31(4):419-22 [12361077.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):672-4 [12618872.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1885-97 [12738747.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):99-109 [12895592.001]
  • [Cites] Oral Dis. 2003 Sep;9(5):227-34 [14628889.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):127-37 [14732220.001]
  • [Cites] Oral Oncol. 2004 May;40(5):461-73 [15006617.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):267-83 [15134534.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Jun;28(3):155-9 [1966928.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):862-74 [8492315.001]
  • [Cites] Free Radic Biol Med. 1995 Feb;18(2):185-94 [7744301.001]
  • [Cites] Mol Carcinog. 1996 Aug;16(4):197-202 [8784462.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):304-12 [15743693.001]
  • (PMID = 18687669.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101235
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Plant Extracts; 0 / Zyflamend; 1HGW4DR56D / Leukotriene B4; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC3697064
  •  go-up   go-down


46. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Ramamoorthy S, Liu YT, Luo L, Miyai K, Lu Q, Carethers JM: Detection of multiple human papillomavirus genotypes in anal carcinoma. Infect Agent Cancer; 2010;5:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of multiple human papillomavirus genotypes in anal carcinoma.
  • Infection with human papillomavirus (HPV) is a major risk factor for development of anal squamous cell carcinoma.
  • Despite over 100 genotypes of the virus, HPV 16 and 18 are considered pathogenic as they are seen in the majority of cervical and anal cancers.
  • We aimed to determine the accuracy of our microarray in anal cancer DNA for HPV genotypes compared to the DNA sequencing gold standard.
  • METHODS: We utilized a sensitive microarray platform to classify 37 types of mucosal HPVs including 14 known high-risk and 23 low-risk types based on cervical cancer data.
  • We utilized DNA from pathologically confirmed cases of anal squamous cell carcinoma.
  • RESULTS: HPV was detected in 18/20 (90%) anal cancers.
  • Eighty percent of anal cancers had at least two HPV types.
  • CONCLUSIONS: Microarray technology is an accurate way to screen for various genotypes of HPV in anal cancer, with 100% correlation with genomic DNA detection of HPV.
  • The majority of anal cancers in our study associated with pathogenic HPV 16 and/or 18.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939896.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NCI NIH HHS / CA / R21 CA137346; United States / NIDDK NIH HHS / DK / R24 DK080506
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2964599
  •  go-up   go-down


48. Zawislak AA, Price JH, Dobbs SP, McClelland HR, McCluggage WG: the management of vulval intraepithelial neoplasia in Northern Ireland. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):780-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 52% of the cases, there was multifocal VIN, and in 43%, there was involvement of other sites such as the cervix, vagina, or anal region.
  • During the study period, 18 of 90 patients (20%) for whom follow-up was available developed invasive vulval squamous carcinoma.
  • Most of the vulval cancers were superficially invasive, but three patients died of vulval cancer during the study period.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / pathology. Vulvar Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681760.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • As a result of active antiretroviral therapy, patients infected with HIV are living longer and are consequently at increased risk for development of cancer.


50. Ma J, Harnett KM, Behar J, Biancani P, Cao W: Signaling in TRPV1-induced platelet activating factor (PAF) in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol; 2010 Feb;298(2):G233-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient receptor potential channel, vanilloid subfamily member 1 (TRPV1) receptors were identified in human esophageal squamous epithelial cell line HET-1A by RT-PCR and by Western blot.

  • Hazardous Substances Data Bank. CAPSAICIN .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 1994 Sep;19(9):362-8 [7985229.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 21;1592(2):175-84 [12379481.001]
  • [Cites] Eur J Biochem. 1995 Apr 15;229(2):327-37 [7538076.001]
  • [Cites] J Biol Chem. 1995 Aug 18;270(33):19320-4 [7642608.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1147-58 [8751717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10803-8 [8855261.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Apr;16(4):455-63 [9115757.001]
  • [Cites] Adv Exp Med Biol. 1996;416:5-10 [9131118.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] Pharmacol Rev. 1999 Jun;51(2):159-212 [10353985.001]
  • [Cites] Pain. 2005 Jan;113(1-2):51-60 [15621364.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5408-16 [15958590.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G418-28 [15890711.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):853-63 [16172262.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1675-85 [16285965.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Mar;18(3):263-70 [16462539.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1307-17 [16439466.001]
  • [Cites] IUBMB Life. 2006 May-Jun;58(5-6):328-33 [16754327.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Oct;319(1):117-26 [16807360.001]
  • [Cites] J Biol Chem. 2007 Jun 29;282(26):18793-9 [17488713.001]
  • [Cites] Dig Dis Sci. 2007 Aug;52(8):1861-6 [17415649.001]
  • [Cites] Cardiovasc Res. 2008 Jan;77(1):30-4 [18006482.001]
  • [Cites] Cell Mol Life Sci. 2008 Sep;65(17):2637-57 [18463790.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Dec;303(3):1052-60 [12438527.001]
  • [Cites] Neurobiol Dis. 2002 Dec;11(3):355-68 [12586546.001]
  • [Cites] Eur J Biochem. 2003 Jul;270(14):2992-3000 [12846832.001]
  • [Cites] J Allergy Clin Immunol. 2003 Jul;112(1):126-33 [12847489.001]
  • [Cites] Biochem J. 2004 Feb 15;378(Pt 1):1-16 [14653781.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16377-87 [14963041.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1814-9 [15128291.001]
  • [Cites] Int Arch Allergy Immunol. 2004 Jun;134 Suppl 1:37-43 [15166482.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Sep;16(9):897-902 [15316415.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Biol Chem. 1980 Nov 10;255(21):10256-60 [7430122.001]
  • [Cites] Thromb Res. 1982 Mar 1;25(5):375-85 [6803388.001]
  • [Cites] J Biol Chem. 1985 Mar 25;260(6):3440-50 [3838314.001]
  • [Cites] Circulation. 1985 Oct;72(4):713-7 [3928192.001]
  • [Cites] J Clin Invest. 1986 Dec;78(6):1701-6 [3023451.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2520-7 [3029085.001]
  • [Cites] J Clin Immunol. 1987 Mar;7(2):179-84 [3571436.001]
  • [Cites] Prog Neurobiol. 1987;29(4):321-64 [3303136.001]
  • [Cites] J Immunol. 1988 May 1;140(9):3161-6 [3361129.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17381-4 [2170377.001]
  • [Cites] Biochem Pharmacol. 1990 Nov 1;40(9):2013-21 [2173598.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):365-71 [1703038.001]
  • [Cites] J Allergy Clin Immunol. 1991 Nov;88(5):749-58 [1659593.001]
  • [Cites] Am J Physiol. 1994 May;266(5 Pt 1):G767-74 [8203523.001]
  • [Cites] Gut. 2008 Dec;57(12):1654-64 [18682519.001]
  • [Cites] Mol Endocrinol. 2008 Dec;22(12):2759-65 [18845671.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G135-43 [19389802.001]
  • [Cites] Science. 1999 Oct 22;286(5440):785-90 [10531066.001]
  • [Cites] Biochem Biophys Res Commun. 2000 May 19;271(3):812-7 [10814544.001]
  • [Cites] Arch Dermatol Res. 2000 May;292(5):256-9 [10867814.001]
  • [Cites] Annu Rev Biochem. 2000;69:419-45 [10966465.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:471-505 [11264466.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11021-30 [11124944.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1267-76 [11579135.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(6):1253-62 [11704645.001]
  • [Cites] Crit Care Med. 2002 May;30(5 Suppl):S294-301 [12004251.001]
  • [Cites] Biochim Biophys Acta. 1995 Feb 9;1254(3):231-49 [7857964.001]
  • (PMID = 19959817.001).
  • [ISSN] 1522-1547
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK057030; United States / NIDDK NIH HHS / DK / R01 DK080703; United States / NIDDK NIH HHS / DK / R01-DK-080703; United States / NIDDK NIH HHS / DK / R01-DK-57030
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Platelet Activating Factor; 0 / Pyridines; 0 / SB 203580; 0 / Sensory System Agents; 0 / TRPV Cation Channels; 0 / TRPV1 protein, human; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; S07O44R1ZM / Capsaicin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2822503
  •  go-up   go-down


51. Botelho M, Oliveira P, Gomes J, Gartner F, Lopes C, da Costa JM, Machado JC: Tumourigenic effect of Schistosoma haematobium total antigen in mammalian cells. Int J Exp Pathol; 2009 Aug;90(4):448-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schistosoma haematobium is endemic in several regions of Africa and has been shown to be associated with predominantly squamous cell bladder carcinoma.
  • The mechanisms underlying the association between S. haematobium and bladder squamous cell carcinoma is largely unknown.
  • All the reports so far, demonstrate exclusively an epidemiological evidence linking S. haematobium infection with squamous cell bladder carcinoma.
  • [MeSH-major] Antigens, Helminth / pharmacology. Carcinoma, Squamous Cell / microbiology. Schistosoma haematobium / pathogenicity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / microbiology
  • [MeSH-minor] Animals. Antigens, Nuclear / analysis. CHO Cells. Carcinogenicity Tests. Cell Proliferation. Cricetinae. Cricetulus. Immunohistochemistry. Male. Mice. Mice, Nude. Models, Animal. Random Allocation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Parasitol. 2001 Apr;17(4):172-5 [11282506.001]
  • [Cites] Urol Int. 2008;80(1):90-7 [18204241.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1268-74 [15154012.001]
  • [Cites] Infect Immun. 1982 Oct;38(1):103-8 [6890530.001]
  • [Cites] Ciba Found Symp. 1983;99:190-206 [6557014.001]
  • [Cites] J Immunol. 1986 Feb 1;136(3):1100-6 [3510253.001]
  • [Cites] Histochem J. 1986 Jan;18(1):5-14 [2423479.001]
  • [Cites] Am J Trop Med Hyg. 1986 Nov;35(6):1185-91 [3098125.001]
  • [Cites] J Immunol. 1990 Jan 1;144(1):317-22 [2153167.001]
  • [Cites] Pathol Res Pract. 1989 Dec;185(6):878-85 [2616372.001]
  • [Cites] Anal Quant Cytol Histol. 1992 Aug;14(4):312-9 [1388568.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1485-9 [9276620.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jan;49(1):17-20 [16625965.001]
  • [Cites] BMC Gastroenterol. 2006;6:13 [16584555.001]
  • [Cites] Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):133-8 [11388504.001]
  • (PMID = 19659903.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  • [Other-IDs] NLM/ PMC2741155
  •  go-up   go-down


52. Romassi M, Nagle D: Images in HIV/AIDS. The changing face of anal cancer. AIDS Read; 2008 Apr;18(4):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in HIV/AIDS. The changing face of anal cancer.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis


53. Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA: Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg; 2006 Aug;76(8):715-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of anal intra-epithelial neoplasia.
  • BACKGROUND: Anal intra-epithelial neoplasia (AIN) is believed to be a precursor to squamous cell carcinoma of the anus.
  • The risk of developing anal cancer in patients with AIN, although known to occur, has been thought to be relatively low.
  • The patients at risk of developing squamous cell carcinoma were the immunocompromised and those with genital intra-epithelial field change.
  • [MeSH-major] Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916390.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


54. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Our previous study using proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell lines.
  • In the current study, to determine the potential involvement of stathmin in OSCC, we evaluated the state of stathmin protein and mRNA expression in OSCC-derived cell lines and human primary OSCCs.
  • A significant increase in stathmin expression was observed in all OSCC-derived cell lines examined compared to human normal oral keratinocytes.
  • These results suggest that expression of stathmin could contribute to cancer progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


55. Kreuter A, Hochdorfer B, Brockmeyer NH, Altmeyer P, Pfister H, Wieland U, Competence Network HIV/AIDS: A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Arch Dermatol; 2008 Mar;144(3):366-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome.
  • Patients with EV usually have a selective defect in cell-mediated immunity.
  • Although skin cancer frequently develops in the sun-exposed cutaneous lesions of patients with EV, the anogenital area is usually not affected by squamous cell carcinomas related to mucosal HPV types.
  • OBSERVATIONS: We report the case of a patient with clinical similarities to EV who also presented with primary lymphedema, anogenital dysplasias, and depressed cell-mediated immunity.
  • CONCLUSIONS: To our knowledge, only 1 other similar case of an EV-like syndrome with impaired, cell-mediated immunity and primary lymphedema has been described in the literature.
  • [MeSH-minor] Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Genitalia, Female / pathology. Humans. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Syndrome

  • Genetic Alliance. consumer health - Lymphedema.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347293.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S: Immune suppression in head and neck cancers: a review. Clin Dev Immunol; 2010;2010:701657
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer in the world.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Head and Neck Neoplasms / immunology. Tumor Escape

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9281-9 [16982773.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):705-13 [16864600.001]
  • [Cites] J Dent Res. 2006 Dec;85(12):1061-73 [17122156.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):315-22 [16967326.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4409-13 [17201162.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2553-62 [12171883.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5069-75 [12208763.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):350-5 [19383307.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):75-81 [12495737.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):882-8 [12925349.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6478-87 [14559840.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):69-76 [14657228.001]
  • [Cites] Int J Mol Med. 2004 Feb;13(2):267-72 [14719133.001]
  • [Cites] Int J Exp Pathol. 2003 Dec;84(6):259-65 [14748745.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5101-10 [15297413.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):25-33 [18298326.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):11-8 [18308558.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1133-8 [18505048.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3706-15 [18559587.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Jan;106(1):27-33 [1734363.001]
  • [Cites] J Oral Pathol Med. 1992 Mar;21(3):100-4 [1374796.001]
  • [Cites] J Surg Oncol. 1993 Jun;53(2):92-6 [8501912.001]
  • [Cites] J Oral Pathol Med. 1994 Feb;23(2):55-9 [8164153.001]
  • [Cites] In Vivo. 1994 Jul-Aug;8(4):543-7 [7893981.001]
  • [Cites] In Vivo. 1995 May-Jun;9(3):225-9 [8562888.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):436-40 [8630949.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):333-8 [8707405.001]
  • [Cites] Crit Rev Oral Biol Med. 1996;7(1):36-58 [8727106.001]
  • [Cites] Acta Otolaryngol. 1995 Nov;115(6):830-2 [8749207.001]
  • [Cites] Curr Opin Immunol. 1997 Feb;9(1):10-6 [9039784.001]
  • [Cites] Mod Pathol. 1997 Nov;10(11):1128-33 [9388064.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] J Immunother. 1998 Jul;21(4):295-306 [9672851.001]
  • [Cites] J Cutan Pathol. 1998 Oct;25(9):463-8 [9821075.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5356-64 [10537320.001]
  • [Cites] Acta Otolaryngol. 1999;119(6):732-8 [10587010.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2065-6 [10601369.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2779-87 [15546137.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1219-23 [12375023.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1219-26 [15549123.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):617-22 [17262084.001]
  • [Cites] J Cell Physiol. 2007 May;211(2):273-8 [17311299.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Feb;29(1):57-62 [17375875.001]
  • [Cites] Head Neck. 2010 Jul;32(7):946-58 [20191626.001]
  • [Cites] J Cancer Res Clin Oncol. 2011 Jan;137(1):173-81 [20376678.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2015-23 [10706869.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2794-802 [10914726.001]
  • [Cites] J Exp Med. 2000 Nov 6;192(9):1213-22 [11067871.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6811-7 [11156370.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2136-47 [11391595.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):781-5 [11519037.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):43-50 [11926411.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):545-57 [12014622.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1787-93 [12060618.001]
  • [Cites] Clin Exp Metastasis. 2002;19(3):247-58 [12067205.001]
  • [Cites] Histopathology. 2002 Aug;41(2):152-7 [12147093.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5344-7 [9850063.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1111-6 [9849463.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):329-34 [10037182.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(2):83-8 [10202560.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1263-73 [10389908.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3468-74 [10416612.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(6):299-302 [10456279.001]
  • [Cites] Cancer Immunol Immunother. 1999 Oct;48(7):346-52 [10501846.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(8):384-7 [10525939.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8126-9 [15520225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Nov;131(5):573-6 [15523428.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1269-75 [15545580.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1984-91 [16284959.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3402-9 [16517708.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Head Neck. 2006 May;28(5):462-70 [16284974.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3890-5 [16818683.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3A):1833-48 [16827115.001]
  • [Cites] Immunol Rev. 2006 Aug;212:314-29 [16903923.001]
  • [Cites] Oral Dis. 2006 Sep;12(5):455-62 [16910915.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1137-46 [17476343.001]
  • [Cites] Cancer Immunol Immunother. 2007 Sep;56(9):1429-42 [17265021.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):977-83 [17617589.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54 [17671115.001]
  • [Cites] Acta Otolaryngol. 2007 Sep;127(9):980-7 [17712679.001]
  • [Cites] Head Neck. 2007 Sep;29(9):874-84 [17315170.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6301-11 [17975141.001]
  • [Cites] Head Neck. 2008 Feb;30(2):251-61 [18172882.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):527-35 [18292929.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):277-85 [17475541.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Feb;132(2):309-16 [15692546.001]
  • [Cites] Cancer Immunol Immunother. 2004 Dec;53(12):1055-67 [15095020.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1010-20 [15709166.001]
  • [Cites] Laryngoscope. 2005 Mar;115(3):522-7 [15744170.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):913-20 [15714205.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jan;24(1):95-105 [15785875.001]
  • [Cites] Semin Immunol. 2005 Aug;17(4):273-83 [15953735.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3045-52 [16116192.001]
  • [Cites] Med Sci Monit. 2005 Aug;11(8):BR280-92 [16049374.001]
  • [Cites] Immunol Res. 2005;33(2):113-33 [16234579.001]
  • [Cites] Acta Otolaryngol. 2005 Dec;125(12):1337-44 [16303684.001]
  • [Cites] Cell Oncol. 2005;27(4):203-13 [16308469.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11146-55 [16322265.001]
  • [Cites] Swed Dent J Suppl. 2005;(179):1-66 [16335030.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Nov;262(11):917-20 [15924277.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):183-93 [16125469.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1123-31 [16424049.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):465-72 [16428488.001]
  • [Cites] Oral Oncol. 2008 Jul;44(7):672-82 [17996489.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3128-37 [18474878.001]
  • [Cites] Ann Diagn Pathol. 2008 Oct;12(5):322-7 [18774493.001]
  • [Cites] J Oral Pathol Med. 2008 Sep;37(8):485-9 [18355177.001]
  • [Cites] Crit Rev Immunol. 2008;28(3):201-13 [19024345.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):186-92 [19064967.001]
  • [Cites] J Immunol. 2009 Feb 1;182(3):1469-80 [19155494.001]
  • [Cites] Head Neck. 2009 Mar;31(3):318-27 [19072995.001]
  • [Cites] Head Neck. 2009 Mar;31(3):371-80 [19073006.001]
  • [Cites] J Craniofac Surg. 2009 Mar;20(2):287-9 [19218858.001]
  • [Cites] J Otolaryngol Head Neck Surg. 2009 Feb;38(1):119-25 [19344621.001]
  • [Cites] Hum Immunol. 2009 May;70(5):289-93 [19217922.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] Immunol Lett. 2009 Apr 27;123(2):97-102 [19428556.001]
  • [Cites] Int J Surg Pathol. 2009 Jun;17(3):244-9 [19443887.001]
  • [Cites] J Laryngol Otol Suppl. 2009;(31):5-10 [19460197.001]
  • [Cites] Head Neck. 2009 Jul;31(7):911-8 [19283850.001]
  • [Cites] Cancer Epidemiol. 2009 Aug;33(2):118-22 [19679058.001]
  • [Cites] Biochim Biophys Acta. 2009 Aug;1796(1):11-8 [19269310.001]
  • [Cites] Oral Oncol. 2009 Oct;45(10):e167-74 [19576838.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6348-57 [19825957.001]
  • [Cites] Indian J Med Res. 2009 Sep;130(3):266-76 [19901436.001]
  • [Cites] Immunology. 2009 Nov;128(3):439-50 [20067543.001]
  • [Cites] Eur J Dermatol. 2010 Jan-Feb;20(1):16-23 [19850548.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2010 Mar;267(3):335-44 [19967383.001]
  • [Cites] Mol Cancer. 2010;9:4 [20064222.001]
  • [Cites] Immunol Rev. 2010 Mar;234(1):45-54 [20193011.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Mar;3(3):266-78 [20179299.001]
  • [Cites] Cell. 2010 Apr 2;141(1):39-51 [20371344.001]
  • [Cites] J Med Virol. 2010 May;82(6):1017-23 [20419817.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):865-78 [15118842.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Oral Pathol Med. 1991 Feb;20(2):49-52 [2016696.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Sep;117(9):1007-10 [1910715.001]
  • (PMID = 21437225.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC3061296
  •  go-up   go-down


57. Fesneau M, Champeaux-Orange E, Hennequin C: [Anal cancer]. Cancer Radiother; 2010 Nov;14 Suppl 1:S120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer].
  • [Transliterated title] Cancer du canal anal.
  • Anal canal epidermoid carcinomas represent 1.2% of digestive cancers and 6% of ano-rectal cancers.
  • The recommended treatment dose is 45 Gy in the anal canal, the mesorectum, pararectal lymph nodes, and inguinal lymph nodes.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21129654.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


58. Islam MN, Kornberg L, Veenker E, Cohen DM, Bhattacharyya I: Anatomic site based ploidy analysis of oral premalignant lesions. Head Neck Pathol; 2010 Mar;4(1):10-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well established that early detection can dramatically improve the 5-year survival rates for oral squamous cell carcinomas.
  • [MeSH-major] Aneuploidy. Carcinoma, Squamous Cell / pathology. Leukoplakia / pathology. Mouth / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1961 Apr;112:411-20 [13750550.001]
  • [Cites] Int J Oncol. 2001 Nov;19(5):1063-8 [11605010.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1927 [17079770.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):310-6 [16931117.001]
  • [Cites] Oral Oncol. 2007 Apr;43(4):366-72 [16931118.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S19.e1-12 [17257863.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):245-52 [11774271.001]
  • [Cites] CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215 [12139232.001]
  • [Cites] Anal Cell Pathol. 2003;25(4):159-66 [14501082.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2306-9 [14556921.001]
  • [Cites] J Dent Res. 2003 Nov;82(11):923-8 [14578507.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Cancer. 1975 Oct;36(4):1386-92 [1175136.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1978 Oct;46(4):518-39 [280847.001]
  • [Cites] J Dent Assoc S Afr. 1991 May;46(5):261-5 [1962315.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):433-40 [8864734.001]
  • [Cites] Anal Quant Cytol Histol. 1997 Aug;19(4):338-44 [9267567.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5B):3645-50 [9854471.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):181-7 [10366450.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):195-204 [10379865.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):319-25 [11319171.001]
  • [Cites] Oral Dis. 2001 Jan;7(1):18-24 [11354915.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4490-6 [11389080.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2148-55 [11391596.001]
  • [Cites] Acta Odontol Scand. 1963 Nov;21:407-14 [14110648.001]
  • (PMID = 20237983.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Feulgen stain; 0 / Rosaniline Dyes
  • [Other-IDs] NLM/ PMC2825532
  •  go-up   go-down


59. Trautmann TG, Zuger JH: Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol; 2005 Jul-Aug;7(4):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal.
  • PURPOSE: In recent years, combined modality therapy (CMT) with chemotherapy and radiation has replaced surgery as the preferred treatment for cancer of the anal canal.
  • PATIENTS AND METHODS: From September 1999 to August 2002, 21 patients with cancer of the anal canal were studied prospectively.
  • CONCLUSIONS: FDG-PET, in conjunction with CT scanning, provides additional staging information in cancer of the anal canal.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Anus Neoplasms / pathology. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):83-101 [14766127.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):590-4 [10853816.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):613-20 [9416407.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):41-5 [10458216.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3995-4000 [14581422.001]
  • (PMID = 16028002.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Jahan I, Fujimoto J, Alam SM, Sato E, Tamaya T: Role of protease activated receptor-2 in lymph node metastasis of uterine cervical cancers. BMC Cancer; 2008;8:301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Receptor, PAR-2 / metabolism. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2003 Jul;23(1):61-6 [12792776.001]
  • [Cites] J Histochem Cytochem. 1998 Feb;46(2):157-64 [9446822.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20927-34 [15010475.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1401-6 [15138580.001]
  • [Cites] Mol Cancer Res. 2004 Jul;2(7):395-402 [15280447.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1013-6 [15492786.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1584-93 [2418947.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1267-81 [10725339.001]
  • [Cites] J Neural Transm (Vienna). 2001;108(2):125-40 [11314768.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):245-82 [11356985.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2031-41 [11395381.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):772-9 [11531266.001]
  • [Cites] Life Sci. 2002 Feb 8;70(12):1359-67 [11883712.001]
  • [Cites] FEBS Lett. 2002 Jul 17;523(1-3):85-9 [12123809.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6 [12231560.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):703-13 [12548614.001]
  • [Cites] Gynecol Oncol. 1987 Jun;27(2):150-8 [3570054.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Semin Diagn Pathol. 1990 Aug;7(3):173-89 [2218146.001]
  • [Cites] Cancer Metastasis Rev. 1992 Mar;11(1):31-44 [1511495.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):157-64 [9600824.001]
  • [Cites] Int J Pancreatol. 1998 Oct;24(2):97-102 [9816542.001]
  • [Cites] Cancer Lett. 1999 May 3;139(1):109-13 [10408902.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):307-14 [16397244.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):139-44 [16425301.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):268-78 [16816379.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4592-8 [10671485.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):84-9 [7556175.001]
  • [Cites] Biochem J. 1996 Mar 15;314 ( Pt 3):1009-16 [8615752.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):437-42 [12966163.001]
  • (PMID = 18937843.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, PAR-2
  • [Other-IDs] NLM/ PMC2587477
  •  go-up   go-down


61. Seth A, Agarwal A: Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study. J Lab Physicians; 2009 Jan;1(1):11-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The study aims to find out if a correlation between apoptotic count and histological grading exists in squamous cell carcinoma of the esophagus, and also to review the literature on such a relationship in the context of some other tumors.
  • SETTINGS AND DESIGN: Cases of squamous cell carcinoma of the esophagus who presented at a tertiary care center over a period of one year were reviewed.
  • MATERIALS AND METHODS: The endoscopic biopsy specimens of 56 patients of squamous cell carcinoma of esophagus were fixed in 10% buffered formalin, processed for routine paraffin sections, sections taken, stained by hematoxylin and eosin and examined under light microscope, using 40× objective and 10× eyepiece.
  • CONCLUSIONS: Grading of squamous cell carcinoma of esophagus, solely on the basis of apoptotic count can be used in the first place or to corroborate conventional histological grading done on the basis of morphology.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2123-8 [10928164.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):88-101 [8990145.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Jul;44(3):257-9 [12024908.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1036-44 [17643097.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Stroke. 1995 Jul;26(7):1252-7; discussion 1257-8 [7541573.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):826-31 [7790118.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jan;121(1):54-8 [9111093.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):901-11 [9265655.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Apr;24(2):73-80 [12026053.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Dec;34(8):900-6 [15907374.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):19-20 [8538735.001]
  • [Cites] Histopathology. 1995 Nov;27(5):469-72 [8575739.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2470-5 [8630413.001]
  • [Cites] Indian J Pathol Microbiol. 2000 Jul;43(3):271-5 [11218671.001]
  • (PMID = 21938242.001).
  • [ISSN] 0974-2727
  • [Journal-full-title] Journal of laboratory physicians
  • [ISO-abbreviation] J Lab Physicians
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167958
  • [Keywords] NOTNLM ; Apoptotic count / histological grading / squamous cell carcinoma esophagus
  •  go-up   go-down


62. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G: Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3355-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma.
  • We have evaluated the effect of T-cell subsets on survival in patients with anal squamous cell carcinoma following radiochemotherapy.
  • METHODS: Biopsy specimens from 38 patients with anal carcinomas were evaluated using tissue microarrays and immunohistochemistry for the presence of tumor-infiltrating immune cells using CD3, CD4, CD8, and CD68 antibodies.
  • CONCLUSIONS: TILs were identified as negative prognostic indicators in anal squamous cell carcinomas with granzyme B+ cytotoxic cells showing highest effect on outcome.
  • This is possibly explained by the selection of therapy-resistant tumor cell clones.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Regulatory / immunology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740757.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Tsai TF, Kuo GT, Kuo LT, Hsiao CH: Prevalence status and association with human papilloma virus of anal squamous proliferative lesions in a patient sample in Taiwan. Sex Transm Dis; 2008 Aug;35(8):721-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence status and association with human papilloma virus of anal squamous proliferative lesions in a patient sample in Taiwan.
  • BACKGROUND AND OBJECTIVE: Anal squamous proliferative lesions, including condyloma, anal high-grade squamous intraepithelial lesion (AHSIL) and squamous cell carcinoma (SCC), are associated with human papilloma virus (HPV) infection.
  • The objectives of the study were to investigate the HPV prevalence of anal squamous proliferative lesion in Taiwan.
  • RESULTS: Anal condyloma mainly occurred in young males, but AHSIL and anal SCC developed in older patients.
  • Multiple HPV infection was found in AHSIL (4 of 12) and condyloma (11 of 34) but was rare in invasive cancer (1 of 12).
  • In our study, emerging HIV-positive AHSIL in recent years indicates that we should devote more efforts to promote sexual safety among the people who engaged in anal intercourse.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Warts / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Warts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650771.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


64. Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S: Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer; 2010 Dec 07;103(12):1858-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.
  • BACKGROUND: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC).
  • METHODS: an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.
  • CONCLUSIONS: an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer.
  • [MeSH-major] Anus Neoplasms / mortality. Biomarkers, Tumor. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Angiogenesis. 2008;11(4):321-35 [18925424.001]
  • [Cites] Mol Carcinog. 2009 Jan;48(1):45-55 [18506774.001]
  • [Cites] Pathol Oncol Res. 2008 Dec;14(4):345-54 [18493868.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(1):31-9 [19221643.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 May;37(5):544-56 [19233691.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1792(4):229-39 [19419697.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3725-32 [19458054.001]
  • [Cites] Curr Drug Targets. 2009 Jul;10(7):581-9 [19601762.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):1001-10 [19796752.001]
  • [Cites] Adv Genet. 2009;67:1-27 [19914448.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6213-21 [19884544.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):361-8 [20010949.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Cancer Biol Ther. 2010 Jan;9(1):23-30 [19923884.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):618-35 [15234243.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):563-9 [15289857.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1239-44 [15292923.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):782-5 [3367186.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1083-93 [2525423.001]
  • [Cites] Clin Cancer Res. 2010 Mar 15;16(6):1745-55 [20215558.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Dig Dis Sci. 2010 Apr;55(4):1098-105 [19399614.001]
  • [Cites] Head Neck Oncol. 2010;2:8 [20398256.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):24-35 [20530316.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Clin Chem. 2000 Mar;46(3):313-8 [10702516.001]
  • [Cites] J Surg Oncol. 2000 Jun;74(2):163-6 [10914829.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9 [11098307.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1768-72 [11100055.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):117-22 [11223026.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Dec;19(4):471-5 [11277325.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Histopathology. 2001 Jul;39(1):43-9 [11454043.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1355-8 [11677963.001]
  • [Cites] Nat Rev Neurosci. 2002 Jan;3(1):24-33 [11823802.001]
  • [Cites] Cancer Lett. 2002 May 8;179(1):1-14 [11880176.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] Med Oncol. 2003;20(3):221-31 [14514971.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6489-96 [14695153.001]
  • [Cites] Dis Colon Rectum. 1991 Feb;34(2):126-31 [1993409.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1251-7 [1650445.001]
  • [Cites] EMBO J. 1992 Mar;11(3):961-71 [1312467.001]
  • [Cites] Acta Oncol. 1992;31(3):333-5 [1622654.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):98-102 [7691975.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):697-709 [7881344.001]
  • [Cites] Cancer Metastasis Rev. 1995 Mar;14(1):3-15 [7606818.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1096-100 [7576999.001]
  • [Cites] Virchows Arch. 1996 May;428(2):85-9 [8925129.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):369-73 [8784470.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int Surg. 1997 Jul-Sep;82(3):275-9 [9372374.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1333-6 [9579842.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1831-5 [9815570.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14 [10487550.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Acta Histochem. 2005;107(2):87-93 [15950051.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):443-9 [16865241.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1728-43 [16815701.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] BMC Med Res Methodol. 2007;7:10 [17302989.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):376-86 [18223558.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1264-73 [18349847.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):946-53 [18396036.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • (PMID = 21063399.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC3008609
  •  go-up   go-down


65. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H: Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis; 2006 Jul 15;43(2):223-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review.
  • Individuals with human immunodeficiency virus (HIV) infection are at increased risk for human papillomavirus-related squamous cell cancer of the anus.
  • Screening HIV-infected patients for squamous cell cancer of the anus and human papillomavirus-related anal dysplasia may prevent excess morbidity and mortality.
  • We have conducted a systematic review of the indirect evidence in the literature regarding the utility of anal Papanicolau (Pap) smear screening of HIV-infected individuals in the highly active antiretroviral therapy era.
  • Although there are no published studies evaluating the efficacy of anal Pap smear screening for preventing squamous cell cancer of the anus or anal intraepithelial neoplasia, we reviewed data regarding the burden of disease, anal Pap smear sensitivity and specificity, the prevalence of anal dysplasia, and 1 cost effectiveness study.
  • The available evidence demonstrates that HIV-infected individuals have an increased risk for squamous cell cancer of the anus and anal intraepithelial neoplasia.
  • This review identifies important areas for further study before routine anal Pap smear screening can be recommended.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. HIV Infections / complications. Papanicolaou Test. Papillomavirus Infections / diagnosis. Precancerous Conditions / diagnosis. Vaginal Smears


66. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A: Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci; 2010 Apr;55(4):1098-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.
  • Large primary tumor and clinical nodal involvement in patients with anal carcinoma treated with chemoradiation are associated with poor disease-free survival (DFS).
  • We analyzed clinical and biomarker data in 30 patients with anal carcinoma who had chemoradiation.
  • Patient selection was based on the availability of untreated cancer for biomarkers, completion of prescribed chemoradiation, and patient outcomes (~50% disease-free) nonrepresentative of published cohorts but conducive to biomarker discovery.
  • Upon further expansion and validation, these results may provide a biomarker-based understanding of heterogeneous clinical biology of patients with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hedgehog Proteins / analysis. Ki-67 Antigen / analysis. NF-kappa B / analysis. Transcription Factors / analysis
  • [MeSH-minor] Anal Canal / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic / pathology. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Immunoenzyme Techniques. Prognosis. Radiotherapy Dosage. Zinc Finger Protein GLI1

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2001 May;59(5):1165-70 [11306700.001]
  • [Cites] J Cell Biol. 1995 Mar;128(6):1111-9 [7896875.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):681-2 [2259380.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23 (22):8070-83 [14585967.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5407-11 [1394146.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] J Clin Invest. 1991 Aug;88(2):691-5 [1864978.001]
  • [Cites] Curr Opin Oncol. 1995 Nov;7(6):541-6 [8547403.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7785-91 [11691793.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3322-30 [18362212.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):1-15 [8557188.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Mar;8(2):87-97 [18336191.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3092-8 [12789286.001]
  • [Cites] Mol Biol Cell. 2002 Oct;13(10 ):3431-40 [12388747.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • (PMID = 19399614.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Ki-67 Antigen; 0 / NF-kappa B; 0 / SHH protein, human; 0 / Transcription Factors; 0 / Zinc Finger Protein GLI1; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


67. Loddenkemper C, Keller S, Hanski ML, Cao M, Jahreis G, Stein H, Zeitz M, Hanski C: Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int J Cancer; 2006 Jun 1;118(11):2750-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the animals fed the nonsupplemented diet, 46% developed colorectal adenocarcinomas and 54% anal-rectal squamous cell carcinomas.
  • Among the mice fed with UDCA, none developed adenocarcinomas and 20% squamous carcinomas.
  • [MeSH-minor] Administration, Oral. Animals. Bile Acids and Salts / analysis. Cell Transformation, Neoplastic. Colon / chemistry. Colon / pathology. Disease Models, Animal. Female. Mice. Mice, Inbred C57BL

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16385573.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


68. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H: High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig; 2007 Mar;11(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Tenascin / analysis

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):986-90 [15094113.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):505-10 [10762653.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2 [16918607.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):719-22 [12209613.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Biochem Cell Biol. 1997;75(6):759-69 [9599665.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):680-7 [9495234.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]
  • [Cites] J Oral Pathol Med. 1994 Nov;23(10):446-50 [7532219.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • [Cites] Gen Dent. 2002 Nov-Dec;50(6):500-3 [12572180.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]
  • (PMID = 17111122.001).
  • [ISSN] 1432-6981
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  •  go-up   go-down


69. Rosty C, Aubriot MH, Cappellen D, Bourdin J, Cartier I, Thiery JP, Sastre-Garau X, Radvanyi F: Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer; 2005;4(1):15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Mutation / genetics. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Squamous Cell / genetics. Neoplasms, Squamous Cell / pathology. RNA, Messenger / genetics. Serine / genetics. Survival Rate

  • Hazardous Substances Data Bank. L-SERINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7094-104 [16007141.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1336-43 [12953088.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5206-11 [7923141.001]
  • [Cites] Hum Mol Genet. 1995 Nov;4(11):2175-7 [8589699.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):323-30 [9018118.001]
  • [Cites] Trends Genet. 1997 May;13(5):178-82 [9154000.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5543-6 [11114733.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1848-9 [11078763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1955-9 [11395371.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4416-8 [11466624.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2555-61 [11745189.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):45-9 [11904459.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15962-70 [11827956.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Eur J Hum Genet. 2002 Dec;10(12):819-24 [12461689.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):260-4 [9207791.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2613-9 [9704710.001]
  • [Cites] Am J Hum Genet. 1999 Mar;64(3):722-31 [10053006.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):18-20 [10471491.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17344-9 [12624096.001]
  • (PMID = 15869706.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 452VLY9402 / Serine; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  • [Other-IDs] NLM/ PMC1131920
  •  go-up   go-down


70. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • METHODS: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery


71. Pepek JM, Willett CG, Czito BG: Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw; 2010 Jan;8(1):123-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy advances for treatment of anal cancer.
  • Radiation therapy (RT) is established as the primary treatment of squamous cell carcinoma of the anus.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064294.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


72. Shpitzer T, Bahar G, Feinmesser R, Nagler RM: A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol; 2007 Sep;133(9):613-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive salivary analysis for oral cancer diagnosis.
  • PURPOSE: This study utilized comprehensive salivary analysis to evaluate biochemical and immunological parameters in the saliva of oral squamous cell carcinoma (OSCC) patients.
  • RESULTS: In cancer patients, salivary median total protein concentration was significantly higher by 26% (P = 0.01), as were concentrations of Na, Ca, P and Mg by 14% (P = 0.05), 59% (P = 0.05), 39% (P = 0.08) and 28% (P = 0.12), respectively.
  • CONCLUSIONS: Comprehensive salivary analysis revealed an overall altered salivary composition in OSCC, indicating a compromised oral environment in these patients and suggesting salivary analysis as a new diagnostic tool for oral cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Mouth Neoplasms / diagnosis. Saliva / chemistry

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Jan 15;63(2):296-7 [12543777.001]
  • [Cites] Am J Physiol. 1984 Jan;246(1 Pt 2):R35-9 [6696100.001]
  • [Cites] Free Radic Biol Med. 2002 Feb 1;32(3):268-77 [11827752.001]
  • [Cites] J Clin Chem Clin Biochem. 1989 Feb;27(2):97-101 [2787388.001]
  • [Cites] Circ Res. 2000 Feb 4;86(2):125-30 [10666406.001]
  • [Cites] J Lab Clin Med. 2001 May;137(5):363-9 [11329534.001]
  • [Cites] Immunochemistry. 1965 Sep;2(3):235-54 [4956917.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1202-6 [10947989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] Anal Chem. 2005 Aug 1;77(15):4947-54 [16053308.001]
  • [Cites] J Formos Med Assoc. 2005 Jun;104(6):390-7 [16037826.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] J Pathol. 2005 Jan;205(2):145-53 [15641016.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):111-8 [15162153.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jan;122(1):44-51 [10629481.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Sep;126(9):1079-85 [10979120.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):734-43 [15599851.001]
  • [Cites] Biol Psychiatry. 1996 Jun 1;39(11):946-9 [9162206.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3979-84 [16818695.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1341-8 [15846296.001]
  • [Cites] J Toxicol Environ Health A. 2005 Sep;68(17-18):1511-23 [16076763.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):4976-84 [15271882.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):614-9 [10944601.001]
  • [Cites] J Investig Med. 2002 May;50(3):214-25 [12033287.001]
  • [Cites] Growth Factors. 2004 Jun;22(2):89-95 [15253384.001]
  • (PMID = 17479291.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Chan E, Kachnic LA, Thomas CR Jr: Anal cancer: progress on combined-modality and organ preservation. Curr Probl Cancer; 2009 Sep-Oct;33(5):302-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: progress on combined-modality and organ preservation.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy / trends. Proctoscopy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082844.001).
  • [ISSN] 1535-6345
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


74. Mullerat J, Perrett CW, Deroide F, Winslet MC, Bofill M, Poulters LW: The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer. Anticancer Res; 2005 Mar-Apr;25(2A):693-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer.
  • BACKGROUND: While macrophages (CD68+) have been associated with angiogenesis in some inflammatory and neoplastic processes by increasing the release of vascular endothelial growth factor (VEGF), their role in anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma has not been established.
  • This study records macrophage infiltration in anal pre-invasive and invasive lesions in HIV+ and HIV- populations, and determines their relationship with angiogenesis.
  • MATERIALS AND METHODS: Sixty patients (31 HIV+) with AIN and anal SCC were studied.
  • [MeSH-major] Anus Neoplasms / blood supply. Anus Neoplasms / virology. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / virology. HIV Infections / pathology. Macrophages / physiology. Neovascularization, Pathologic / virology
  • [MeSH-minor] Anal Canal / blood supply. Anal Canal / pathology. Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Anus Diseases / pathology. Anus Diseases / virology. Disease Progression. Humans. Immunohistochemistry. Precancerous Conditions / blood supply. Precancerous Conditions / virology. Vascular Endothelial Growth Factor A / biosynthesis. Warts / pathology. Warts / virology

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868898.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


75. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg; 2010 Apr;139(4):984-90; discussion 990
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung.
  • OBJECTIVE: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC).
  • METHODS: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics.
  • For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05).

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):45-56 [16680571.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):941-6 [16538215.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5448-53 [17000679.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2054-60 [17404086.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):52-60 [17625931.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1362-78 [18258475.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1188-94 [18422740.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2185-92 [18823373.001]
  • [Cites] Ann Thorac Surg. 2008 Nov;86(5):1576-83 [19049753.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):67-74 [19331134.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):894-901 [19480010.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2513-7 [19596921.001]
  • [Cites] J Pathol. 2000 Feb;190(2):150-6 [10657012.001]
  • [Cites] Circulation. 2000 Oct 17;102(16):1944-9 [11034943.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3944-8 [11051242.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):421-4 [11182067.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):647-51 [12494473.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):745-51 [12866035.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3098-104 [12912961.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):541-50 [14520690.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):171-9 [15246188.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):461-9 [9234385.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):149-53 [9918213.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):842-9 [15681529.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1086-92 [15709175.001]
  • [Cites] Circulation. 2005 Mar 8;111(9):1166-74 [15723986.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):245-52 [15592677.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1676-84 [15754326.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] Anal Biochem. 2005 Aug 1;343(1):54-65 [15953581.001]
  • [Cites] Am J Cardiol. 2006 Feb 15;97(4):532-7 [16461051.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):313-21 [16423426.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Circulation. 2006 Jul 4;114(1 Suppl):I365-70 [16820601.001]
  • (PMID = 20304142.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL059165; United States / NHLBI NIH HHS / HL / R01 HL059165-11; United States / NHLBI NIH HHS / HL / HL59165; United States / NHLBI NIH HHS / HL / HL81691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS167053; NLM/ PMC2844342
  •  go-up   go-down


76. Cho BC, Ahn JB, Seong J, Roh JK, Kim JH, Chung HC, Sohn JH, Kim NK: Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer; 2008;8:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
  • BACKGROUND: The objectives of this study were to evaluate long-term results of concurrent chemoradiotherapy (CRT) with 5-fluorouracil and cisplatin and the potential benefit of consolidation chemotherapy in patients with anal squamous cell carcinoma (ASCC).
  • CONCLUSION: our study shows that CRT with 5-FU and cisplatin, with or without consolidation chemotherapy, was well tolerated and proved highly encouraging in terms of long-term survival and the preservation of anal function in ASCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Fluorouracil / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):150-6 [1546901.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Radiother Oncol. 1993 Jun;27(3):209-15 [8210457.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):745-9 [8690640.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1099-105 [9392550.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82 [15818867.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2650-7 [16284984.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S123-8 [16399449.001]
  • [Cites] Oncologist. 2007 Apr;12(4):451-64 [17470688.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3229-34 [18490648.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2460-5 [12829663.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2933-9 [12885812.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2057-61 [14647138.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33 [526911.001]
  • [Cites] J Clin Gastroenterol. 1984 Jun;6(3):257-9 [6539351.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3876-85 [3731062.001]
  • [Cites] Am J Med. 1989 Aug;87(2):221-4 [2527006.001]
  • (PMID = 18194582.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2245963
  •  go-up   go-down


77. Baudis M: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer; 2007;7:226
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Related average imbalance patterns were found for clinically distinct entities, e.g. hepatocellular carcinomas (ca.) and ductal breast ca., as well as for histologically related entities (squamous cell ca. of different sites).

  • COS Scholar Universe. author profiles.
  • SciCrunch. BioSharing: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1988 Nov;80(3):235-46 [3192213.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1410-8 [10604741.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):383-99 [10639584.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):871-8 [10702404.001]
  • [Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):29-37 [11790857.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):63-90 [12072205.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):77-87 [12446957.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):494-8 [12712440.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1808-14 [12738738.001]
  • [Cites] Pathologica. 2003 Apr;95(2):71-82 [12768875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1039-44 [14730057.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):143-9 [15140403.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Cytogenet Genome Res. 2004;106(1):43-8 [15218240.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):1-9 [15325087.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):682-7 [15483344.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Clin Genet. 1972;3(3):169-79 [4115505.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Hum Genet. 1993 Feb;90(6):584-9 [8383093.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Hum Mol Genet. 1993 Nov;2(11):1907-14 [8281155.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4813-7 [8062283.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jul 15;82(2):140-5 [7664243.001]
  • [Cites] Blood. 1996 Jan 1;87(1):25-9 [8547649.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):368-75 [8630489.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4 [8981013.001]
  • [Cites] Cytogenet Cell Genet. 1996;75(1):17-21 [8995481.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):406-10 [9090389.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Sep;56(9):999-1008 [9291941.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):372-6 [9408753.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):172-5 [9491330.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):625-37 [9683604.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):307-16 [9824203.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1283-91 [16979954.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]
  • [Cites] J Pathol. 2007 Jan;211(1):18-25 [17072825.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):293-301 [17011066.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):934-44 [16862168.001]
  • [Cites] Bioinformatics. 2007 Feb 15;23(4):450-7 [17150994.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14 [17382262.001]
  • [Cites] Prostate. 2007 May 15;67(7):692-700 [17342750.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2734-8 [17354231.001]
  • [Cites] Pathologe. 2007 Nov;28(6):464-73 [17882420.001]
  • [Cites] Ugeskr Laeger. 2008 Jan 28;170(5):328-30 [18252159.001]
  • [Cites] Hum Genet. 1988 Nov;80(3):224-34 [3192212.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Am J Hum Genet. 1960 Sep;12:250-76 [14430808.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1061-4 [15650359.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):822-7 [15705879.001]
  • [Cites] Acta Pharmacol Sin. 2005 Jun;26(6):659-65 [15916730.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):593-606 [16077907.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):11-9 [16130125.001]
  • [Cites] Biotechniques. 2006 Mar;40(3):269-70, 272 [16568815.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):103-8 [16737908.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):721-30 [16688744.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3961-70 [16818693.001]
  • [Cites] Cell Oncol. 2006;28(3):71-84 [16823176.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4399-412 [16547504.001]
  • [Cites] Bioinformatics. 2006 Aug 15;22(16):1971-8 [16705014.001]
  • [Cites] Cytogenet Genome Res. 2006;115(1):16-22 [16974079.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2308-15 [16728973.001]
  • (PMID = 18088415.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2225423
  •  go-up   go-down


78. Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, Pinheiro DG, Torres C, de Carvalho AF, Cury PM, Nunes FD, Nishimoto IN, Soares FA, da Silva AM, Kowalski LP, Brentani H, Zanelli CF, Silva WA Jr, Rahal P, Tajara EH, Carraro DM, Camargo AA, Valentini SR: Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia; 2009 Dec;11(12):1329-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease affecting the epithelium of the oral cavity, pharynx and larynx.
  • In this study, we combined rapid subtractive hybridization and microarray analysis in a hierarchical manner to select genes that are putatively reactivated by the demethylating agent 5-aza-2'-deoxycytidine (5Aza-dC) in HNSCC cell lines (FaDu, UM-SCC-14A, UM-SCC-17A, UM-SCC-38A).
  • This combined analysis identified 78 genes, 35 of which were reactivated in at least 2 cell lines and harbored a CpG island at their 5' region.
  • Bisulfite sequencing of their CpG islands revealed that they are indeed differentially methylated in the HNSCC cell lines.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA Methylation. GTP-Binding Proteins / genetics. Head and Neck Neoplasms / genetics. Receptors, Retinoic Acid / genetics
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. CpG Islands / genetics. Epigenesis, Genetic. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Myxovirus Resistance Proteins. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis